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Abstract 
 
CD4+ T cell responses are critical components of the immune response to viral infections, yet 
unlike their CD8+ counterparts, CD4+ responses to many viral agents remain 
uncharacterised.  The CD4+ T cell subsets involved in controlling primary and persistent 
EBV infection (causative agent of IM) have not been extensively studied. This investigation 
attempted the first systematic analysis of the CD4+ T cell response to epitopes from across 
the EBV genome in a subset-specific manner. It combined MHC II tetramer technology (nine 
epitopes) with intracellular staining for transcription factors of the Th1/Th2/Treg subsets to 
analyse 8 healthy and 2 IM donors. Although the analysis of Th1/Th2 subsets requires further 
optimisation, MHC II tetramer staining and intracellular staining were successfully combined 
for FOXP3. Evidence is presented for the presence of EBV-specific Treg responses, within 
healthy persistent carriers but the absence of such responses in acute primary IM patients. 
The results implicate that a lack of Tregs, in combination with other genetic factors, may play 
a role in IM development. Preliminary Th1 responses and negative Th2 responses in healthy 
and IM patients were observed. Further understanding the subsets involved in controlling 
EBV, will help focus therapeutic applications towards EBV-associated malignancies at 
specific subsets. 
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1.1 – Epstein-Barr Virus and lifecycle 
Epstein-Barr Virus (EBV) is a widespread γ-herpesvirus with a double stranded (ds) DNA 
genome that infects >90% of the world’s adult population (Reviewed in1). EBV is typically 
acquired in childhood via saliva where it is associated with an asymptomatic infection in the 
vast majority of cases.  
  
Oral transmission (via saliva) of EBV into a naive host results in the initiation of a lytic 
infection within the epithelial cells of the oropharynx characterised by high rates of viral 
shedding, which is slowly brought under control by the mounted immune response. Parallel 
to this lytic infection, the virus infects circulating mucosal B cells and initiates its latent 
growth-transforming programme (Figure 1). EBV expresses a set of latent proteins that then 
drive the proliferation of infected B cells and their differentiation into a pool of memory cells. 
This initial proliferation results in up to as many as 1-10% of the infected host’s total B cell 
count being EBV infected within the blood - which decreases quickly as the infection is 
limited by the T cell response. Within healthy long term carriers, the number of EBV positive 
B cells within the blood are rare at around 1-50 per 10
6
 B cells
2
. 
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Figure 1 - A schematic representation of the primary replication of EBV, long term carriage and reactivation of EBV. 
EBV replicates within the nasopharynx inducing a large CD8 T cell response parallel to infecting local B mucosal cells to 
establish latency. Latent B cells may enter the lytic phase and shed virions into the saliva3. 
  
  
EBV undergoes two different forms of infection: lytic and latent. During lytic infection the 
full cohort of ~60 genes become expressed progressively during the infection separated into: 
immediate early (IE), early (E), and late (L) proteins according to the time of their 
expression. This cohort allows the virus to fully replicate and produce new progeny. The first 
viral gene product to be expressed is the viral transactivator BZLF1 which controls the 
expression of the viral genome. Functions of example of proteins used during the current 
project are shown in Table 1. 
  
Parallel to this lytic infection, the virus expresses a separate smaller cohort of 9 genes that are 
involved in establishing the latent infection within B cells.  All of the latent and lytic proteins 
expressed by EBV are all immunogenic to the host which results in a robust immune 
response that eventually brings the infection under control forming the EBV-specific memory 
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T cell response of the host for life. The loss of this immune control, specifically the adaptive 
T cell response results in clinical disease by EBV.  
 
Once a  pool of latent EBV infected B cells is formed the virus switches off of all gene 
expression to avoid detection by EBV specific T cells and to maintain an infected B cell pool 
that can spontaneously revert to the lytic cycle during the hosts lifetime. Throughout the 
lifetime of the carrier, these latently infected B cells can recirculate back to the nasopharynx 
where they re-establish the lytic cycle of infection by spontaneous reactivation. New progeny 
in the saliva can then be transmitted to a naive host (Figure 1). These subsequent 
reactivations are controlled by the memory T cell response. 
 
As well as its acute capabilities, EBV is the causative agent of the B cell malignancies - 
Hodgkin’s lymphoma and Burkitt's lymphoma - as a result of its B cell growth transforming 
capabilities
2
. Within these different B cell malignancies, EBV infected B cells exhibit a 
different latency programme (described in Table 2) distinguished by the expression of a 
limited and differing panel of the 9 latency genes. 
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Table 1 – Examples and Functions of  EBV lytic and latent proteins2; 7; 8. These proteins were selected as examples due 
to the MHC class II tetramers investigated within this project presenting an epitope from these proteins (Table 3). 
 
 
Table 2 - Growth programmes of EBV and their gene expression combinations9  
 
Protein Infection 
Stage 
Function 
BZLF1 Lytic   IE Viral Transactivator 
BMRF1 “          E“ DNA polymerase activity 4 
BARF1 “          E“ Suspected oncogene activity 5 
BFRF1 “          E“ Recruits nuclear envelope components at the nuclear membrane for 
nuclear release 
6
 
EBNA1 Latent Binds to the viral origin of replication on the viral genome episome to 
ensure the propagation of EBV DNA to daughter cells during host cell 
division 
EBNA2 ‘‘           ‘‘  Transactivator that is the first viral protein expressed during latency 
and essential for cellular transformation 
Type of 
Infection 
Growth Programme Genes Expressed Associated 
Malignancy 
Latent Latency 0 No significant gene 
expression 
- 
Latent Latency I/Latency 
Programme 
EBNA 1 Burkitts lymphoma 
Latent Latency II/Default 
Programme 
LMP1/2 
EBNA 1 
Hodgkin’s lymphoma 
and Nasopharyngeal 
carcinoma 
Latent Latency III/Growth 
Programme 
LMP1/2 
EBNA1/2/3A/3B/3C 
PTLD 
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1.2 - Infectious mononucleosis and EBV association with malignancies 
In the Western world, as a result of improved sanitation, primary infection can be delayed to 
adolescence in up to 25% of patients where a self-limiting acute disease known as 'Infectious 
Mononucleosis' (IM) presents. Symptoms of IM are generally mild including fever, malaise, 
fatigue, sore throat, lymphadenopathy and splenomegaly that all typically resolve after 1 
month. IM provides us with a rare opportunity to follow a genetically stable viral agent from 
primary infection to the establishment of life long latency. This has provided us invaluable 
information on the development of virus specific T cell responses, the kinetics of these 
responses and how these responses change over the course of primary to persistent infection. 
The CD8+/CD4+  T cell responses to EBV have been well documented to alter in their 
magnitude, breadth and immunodominance in IM compared to chronic infection
10
. Within 
IM, it is known that a large expansion of the CD8+, and to a lesser extent the CD4+ T cells 
occurs
11
. This expansion is thought to be responsible for the clinical symptoms.  
 
1.3 - CD8+ T cell response in IM and Healthy Donors 
To date, the most interest has been directed towards the EBV-specific CD8+ T cell response 
primarily due to the large expansions of these cells during IM. In 1996, the development of 
MHC class I tetramers where fluorescently labelled quadramers of HLA class I molecules 
present a peptide from a known EBV epitope, have allowed the extensive and direct visual 
analysis of EBV-specific CD8+ T cells from IM patients to epitopes derived from lytic and 
latent antigens, at the single cell level
12
. There is a marked preference for particular antigens 
of the lytic and latent viral protein classes and the particular immunodominance of CD8+ T 
cells towards epitopes derived from the EBNA3 protein family and the BZLF1 and BRLF1 
IE proteins is observed. With regards to latent antigens, the CD8+ T cell response appears to 
be broadly directed across all nine latent proteins. The responses to lytic antigens compared 
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to latent are generally much larger. Studies have revealed that the EBV-specific CD8+ T cell 
responses in IM may be oligoclonal for a single epitope of the viral genome and that 
responses for an individual lytic epitope can represent up to 40% of the total T cell response 
during IM. The immunodominance hierarchy is a result of the immunoevasive proteins that 
impair the MHC class I (MHC I) antigen presenting pathway (Table 3) and therefore only the 
antigens expressed before the immunevasion proteins interact with MHC I are recognised 
well
13; 14; 15 16
. 
 
1.4 - CD4 T cell response 
CD4+ T cells are recognised for their functions in helping the immune system in response to 
viral infections [Reviewed in
17; 18
]. They promote class switching and affinity maturation of 
antibodies; induce the phagocytic ability of antigen presenting cells (APCs) and increase 
CD8+ T cell cytoxicity. Enhancing the CD8+ T cell cytotoxic effect by the CD4+ T cells 
involves the supply of co-stimulatory molecules, production of pro inflammatory 
cytokines/chemokines and direct cytotoxic effector functions upon target virus infected cells 
themselves. In order to perform these 'helper roles' activated CD4+ T cells undergo a process 
of differentiation into distinct effector subsets
18; 19
 (Figure 2). Each subset expresses a 
characteristic cytokine and master regulator transcription factor (mTF) although it is now 
clear that there is plasticity between the subsets. The two best studied subsets are the T helper 
T cells (Th) 1 and 2. Th1 cells are defined by IFN-γ and TNF-α production and expression of 
the mTF TBet. Their main effector function is promoting a proinflammatory response by 
activating macrophages to attract homing lymphocytes. Responses to viral antigens are 
predominantly of the Th1 response with classically high levels of IFN-ɣ production. Th2 
cells express Interleukin (IL)-4, mTF GATA3 and are associated with allergic and responses 
to extracellular pathogens. T Regulatory cells (Tregs) are important in the suppression of over 
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robust immune responses (both CD4 and CD8) and express the mTF FOXP3. However, 
FOXP3 is not solely expressed in Tregs but as yet is considered the most characteristic 
marker
20
. As a result of their suppressive functions, some viral pathogens are thought to 
promote the differentiation of CD4+ T  cells into Tregs in order to hinder the antiviral 
response that may lead to its elimination from the host 
21
. Two types of Tregs have been 
identified: The first known as the 'natural' Tregs produced within the thymus and the second 
known as the 'adaptive' Tregs which are induced to express the characteristic markers CD25 
and FOXP3 once activated
20
. Th17 cells, characteristically producing IL-17 and the RORγ 
mTF have been implicated in the immunopathology associated with viral infections.  These T 
cells are normally generated in the presence of IL-6 and TGF-β. IL-23 is associated with the 
development of the pathogenic effects of these cells
22
. Follicular helper cells (Tfh) are 
thought to reside in niches within the germinal centres providing help for B cell class 
switching. However it is as yet unclear whether these are a true distinct subset or rather a 
state that is imposed upon the other subsets. Tfh express IL-21 and Bcl6. Finally it has now 
been demonstrated in several contexts that CD4+ T cells can acquire a cytotoxic phenotype. 
Such cytotoxic CD4+ T cells (ThCTL) are reported to be Th1 like producing IFN-γ and exert 
their apoptotic effects on their targets via the release of perforin and granzyme
17
. In the 
context of CD4+ T cells, the presence of IFN-γ during activation favours the development of 
Th1 cells over Th2.  The CD4+ T cell subsets are very fluid and as a result may express more 
than one master regulator and thus express different cytokine combinations. It is therefore 
important to fully characterise the EBV-specific CD4+ T cell response for comparison to that 
of characterised and successful viral vaccine responses. This may facilitate the development 
of an EBV-vaccine that induces a broad and polyfunctional CD4+ /CD8+ responses.  
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Figure 2 - The Roles and subsets of CD4 T cells. A) The helper functions of the CD4 T cells. CD4 T cells promote antiviral 
immunity via many direct and indirect interactions with immune cells. B) The differentiated effector subsets of activated 
CD4 T cells. Subsets are influenced by the cytokine milieu in combination with the mater regulator17. 
 
  
1.5 - CD4+ T cell response to EBV in primary and persistent infection 
To date, the dissection of the CD4+ T cell response to EBV during primary infection has 
been hindered as a consequence of lack of knowledge of individual epitopes and their 
restricting HLA alleles and no available reagents to detect the low frequencies of circling 
EBV-specific CD4+ T cells. As a result, much less is known about the CD4+ EBV T cell 
response regarding its epitope specificity, magnitude and kinetics as compared to the CD8+ T 
cell response. Furthermore, the CD4+ T cell response is slightly more complicated due to the 
presence of the several distinct effector subsets. Interest in the CD4+ T cell  response to EBV 
is now increasing following observations that many EBV-specific CD4+ T cells are able to 
directly recognise EBV-infected cells 
24
 and the  EBV associated lymphomas are MHC class 
II (MHC II)  positive. Within a phase II clinical trial, 33 Post Transplant Lymphoproliferative 
Disease (PTLD) patients were treated with a cytotoxic T cell therapy, more positive 
responses were observed when the T cell transplants contained higher >5% CD4+ T cells
25
.  
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Current analyses of the EBV-specific CD4+ T cell responses have, until recently, been 
carried out using the use of ex vivo functional assays that have mostly monitored the 
production of IFN-γ. This cytokine is characteristic of the Th1 response restricting the 
analysis of the CD4+ T cell response to any given EBV antigen to Th1 cells. However, where 
studied, functional assays have indicated that CD4+ T cell responses towards the latency 
proteins are of the cytotoxic Th1 subset
26
. These functional assays coupled with epitope 
mapping studies (using peptides of 20mers from a range of lytic and latent antigens) have 
allowed for the isolation of EBV specific CD4+ T cell clones and the subsequent 
characterization of their restricting HLA alleles
27
. Thus, recent knowledge of epitopes, TCR 
specificity, restricting MHC (Table 3) and advances in technology have opened the way for 
the generation of MHC II:EBV peptide tetramers. MHC II tetramers display epitopes derived 
from EBV proteins within their peptide binding grooves, allowing characterisation of 
epitope-specific T cells by flow cytometry on a single cell level and removing the reliance on 
functional assays [Reviewed in
28; 29; 30; 31; 32
]. 
 
The uses of MHC II tetramers and IFN-γ readout assays have provided us with the following 
important findings. It has been documented that within IM patients, 2.7% of the circulating 
CD4+ T cells are specific for EBV and directed towards both the lytic and latent classes of 
EBV Ags
33
. Therefore in the context of IM, the EBV-specific CD4+ T cell responses are now 
known to also expand during IM, albeit at a 10 fold lower magnitude compared to the CD8+ 
T cell response with any given antigen
11
. CD4+ T cell responses to lytic antigens do not show 
marked immunodominance towards particular lytic antigens  expressed in a particular phase, 
but rather, a broad response against the range of lytic antigens
34
. In contrast to the CD8+ 
response, CD4+ responses against the latent antigens (EBNA3C and EBNA1) are in higher 
frequency than those against the lytic. The responses to lytic Ags are detectable within the 
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peripheral blood of IM patients and rapidly decline during disease convalescence, whereas 
the CD8+ responses to latent Ags are rarely detected at primary infection and increase over 
the subsequent weeks. With surprising efficiency, CD4+  T cell clones generated against 
EBV epitopes have been shown to be directly cytotoxic against LCLs presenting the correct 
epitope
34; 35; 36
. EBV-specific CD4+ T cells have been demonstrated to recognise virus-
infected cells such as Burkitt lymphoma cell lines  suggesting a potential for these CD4+ T 
cell clones in the treatment of MHC II positive EBV-associated malignancies
37
.   
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Phase of 
Lifecycle 
Protein Region Epitope MHC restricting 
allele 
Lytic BZLF1 61-75 LTA DR52b 
  BMRF1 136-150 VKL DR17 
  BARF1 185-199 SRD DR7 
  BFRF1 125-139 MLG DR7 
Latent EBNA1 474-493 SNP DR51 
  EBNA1 509-528 VYG DR7 
  EBNA2 276-295 PRS DR7 
  EBNA2 276-295 PRS DR52b 
  EBNA2 301-320 PAQ DR17 
Table 3 - CD4 epitopes of EBV lytic and latent antigens. Epitopes are denoted by three letters indicating the first three 
amino acids of their primary sequence11. 
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1. 6 - Aims 
 
We now have the tools that allow us to analyse the EBV-specific CD4+ T cell response at a 
single cell level. Through using MHC II tetramers, we already have an understanding of the 
frequencies and phenotypic characteristics of EBV-specific CD4+ T cells present during 
primary and persistent infection. In this study it was aimed to further characterise these cells 
by investigating the CD4+ T cell subsets present. Understanding the CD4+ T cell subsets 
involved in the control of IM and healthy persistence may help to facilitate the design of 
immunotherapies directed toward EBV proliferative diseases. 
 
The aims of this investigation were as follows: 
 
1. To optimise intracellular staining protocols for antibodies against the master 
transcription factors of the major CD4+ T cell subsets: Tbet (Th1), GATA3 (Th2) and 
FOXP3 (Treg) 
 
2. To analyse the percentage of CD4+ T cells expressing Tbet, GATA3 and FOXP3-
within the total CD4+ T cell pool and EBV MHC II tetramer-positive populations in 
healthy donors 
 
3. To conduct preliminary studies on IM donors to analyse the percentage of  CD4+ T 
cells expressing Tbet, GATA3 and FOXP3 within total CD4+ T cells and EBV MHC 
II tetramer-positive populations 
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Transcription Factor Antibodies Host Clone Company Volume/test 
Alexa Fluor 488 Mouse anti-human 
FOXP3 
Mouse 259D/C7 BD 
Biosciences 
20 μl 
Alexa Fluor 488 Mouse anti GATA3 Mouse L50-823 BD 
Biosciences 
20 μl 
Alexa Fluor 488 Mouse IgG k Isotype 
Control 
Mouse P3.6.2.8.1 BD 
Biosciences 
20 μl 
Anti-Mouse/Human TBet PE Mouse 4B10 eBiosciences 2.5 μl 
Anti-Mouse/Human TBet PerCP-
Cy5.5 
Mouse 4B10 eBiosciences 1.25 μl 
Table 4 - Antibodies used for the staining of intracellular proteins 
  
  
Antigen Fluorchrome Company Volume/test 
CD45RO Pacific Blue Biolegend 2 μl 
CD4 PE BD 2 μl 
CD3 APC Invitrogen 0.5 μl 
CD4 FITC BD Pharmingen 2 μl 
CD4 ECD Beckman 
Coulter 
1 μl 
CD4 PerCp-Cy5.5 eBiosciences 2 μl 
Table 5 -Concentrations of the fluorochromes used for surface staining and or compensation of the multi-colour flow 
cytometry 
  
 
 
Reagent Company 
FCS Gibco 
1 X PBS Dulba 
4% Paraformaldehyde in PBS Sigma 
RPMI 1640 Gibco 
Saponin Sigma (4% stock in PBS 
was made in house) 
Saponin 0.5% FACS buffer  In House 
MACS Buffer (1X PBS, 0.5% BSA, 2mM 
EDTA) 
In House 
FACS buffer In House 
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Human Sera (HuS) TCA 
Goats Sera (Heat Inactivated Normal Goat 
Serum) 
Gibco 
Lymphoprep PAA 
PBS-NGS (1%)-NGS (1%) In House 
Kit Company 
FOXP3 fix/perm staining kit eBiosciences 
Intracellular Fixative (IC) eBiosciences 
Table 6 – Reagents used throughout the investigation 
 
 
2.1 - Preparation of PBMC's from healthy donors 
Heparinised (1:100) blood was collected from EBV-sero positive donors, diluted 1:1 with 
fresh RPMI and layered onto 15 ml of Lymphoprep in a 50ml falcon tube. The tubes 
were centrifuged at 2000 rpm for 30 minutes, at 22
o
C with the brakes off. The 
lymphocytes were carefully aspirated off the interface between the lymphoprep and 
plasma/RPMI. ‘Peripheral Blood Mononuclear Cells’ (PBMCs) were washed twice in 
30ml RPMI and centrifuged at 2000 rpm for 10 minutes at 22
o
C to remove the ficoll and 
the PBMCs were counted on a haemocytometer. PBMCs were then centrifuged at 1600 
rpm for 7 minutes and the pellet resuspended in 10% DMSO freezing medium. 1ml 
resuspended PBMCs were aliquoted to a cryovial, left at -80
o
C overnight before transfer 
to liquid nitrogen for long term storage. 
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2.2 - MHC Class II Tetramer Staining 
Tetramer staining of PBMCs was done prior to the surface and intracellular staining for 
transcription factors. PBMCs were thawed from liquid nitrogen in 1ml of RPMI (10% 
FCS and P/S) and centrifuged at 2000 rpm for 5 minutes at 22
o
C. The PBMCs were then 
counted on a haemocytometer and distributed to FACS tubes. For tetramer staining, a 
minimum of 1 x 10
6
 cells per sample were required (1.5 x 10
6
 cells per sample were used 
to compensate for cell loss during the subsequent washes). Cells were resuspended in 
10ml RPMI (8% FCS), counted and CD8 depleted using CD8 DynaBeads for 30 minutes 
on a rotating shaker in a cold room. For IM patient samples, 3 times the amount of CD8 
depletion beads were used, compared to the healthy donor PBMCs, to accommodate for 
the large CD8 expansion. PBMCs were re-counted and 1.5 x 10
6 
CD8 depleted cells 
transferred to the FACS tubes and 0.5 x 10
6 
for control tubes. Cells were washed in 500μl 
of human serum before adding 1μl of the relevant tetramer, for the peptide under 
investigation, to each tube and incubating for 2 hours at 37
o
C.  
 
Following tetramer staining, the cells were viable and then surface stained (vital dye 
binds only dead cells allowing their elimination  on the LSR II). Vital dye (diluted 1:100) 
was added at 1.5μl to the relevant tubes (excluding unstained control tubes) and 
incubated for 20 minutes at room temperature in the dark.  Cells were washed once in 
PBS, surface antibodies (specific for CD3 and CD4 table 5) were added and incubated 
for 30 minutes on ice to prevent antibody internalisation. Excess antibodies were 
removed by one wash in PBS. Cells were fixed and permeabilised according to one of the 
protocols in 2.3, 2.4 and 2.5.  
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2.3 - Paraformaldehyde (PFA) method for intracellular staining 
Following surface staining, cells were fixed for 20 minutes in 2% PFA (1:1 dilution of 
4% PFA stock to PBS) at room temperature. After fixation, the cells were washed once in 
PBS/2%BSA and then once in 500μl saponin buffer (0.5% final concentration from a 4% 
stock diluted in PBS). The cells were incubated within the residual saponin buffer for 20 
minutes at room temperature before intracellular antibodies were added and the cells 
further incubated for 1 hour in the dark at room temperature. Antibody concentrations 
used were 0.5μg for the TBet PE, 0.25μg for the TBet PerCP-Cy5.5, and 20μl for both 
the FOXP3 and GATA3 antibodies (Table 4). Finally, the cells were washed twice in 
PBS/2% BSA, resuspended in 300μl and kept on ice/4oC in the dark until analysis on the 
LSR II.  
  
2.4 – EBiosciences FOXP3 staining kit 
Following surface staining, the cells were resuspended in 1ml fix/perm buffer (stock 1 in 
4 with diluent) and left on ice for 1 hour in the dark. Cells were washed twice in 1ml of 
perm buffer (at a 1 in 10 dilution with H20) and centrifuged at 1600 rpm for 4 minutes. 
All subsequent wash centrifugations were done at 1600 rpm for 4 minutes. To block any 
unspecific binding sites, the cells were incubated for 15 minutes at room temperature 
with 100μl of perm buffer with mouse serum (diluted 1 in 10 with the perm buffer). After 
incubation, intracellular antibodies were added at the concentrations given in 2.3 and 
incubated for 1 hour at room temperature in the dark. Following incubation, the cells 
were washed twice in 1ml perm buffer, resuspended in 300μl PBS and kept on ice/4oC in 
the dark until analysis on the LSR II.  
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2.5 - EBiosciences intracellular fixative kit for intracellular staining 
Following surface staining, 100μl of eBiosciences intracellular fixative (IC) was added to 
the cells, vortexed well and incubated for 1 hour on ice in the dark (and vortexed after 30 
minutes of the incubation period). After incubation, 100μl of 0.2% Triton-X 100 was 
added to the tubes (final concentration 0.1%) and incubated for 30 minutes on ice in the 
dark. Cells were subsequently washed once in 2ml PBS-NGS-NHS (materials), 
resuspended in 300μl PBS and kept on ice/4oC in the dark until analysis on the LSR II.  
  
2.6 - Flow Cytometry 
The LSR II FACs machine (BD biosciences) was used for analysing multi-colour flow 
cytometry experiments. Compensation beads stained with antibodies (Table 4) were used 
to compensate the different colours involved in each experiment. One drop of each of 
negative and positive beads were added to each compensation tube and stained for 30 
minutes on ice. Data was analysed via FlowJO/DIVA software.  
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CHAPTER 3 - RESULTS 
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3.1 – Optimisation of the intracellular staining protocol  
 
The first step in this investigation was to determine the optimum concentration of each 
antibody that enabled visualisation of cells expressing the relevant transcription factor in 
the absence of non-specific staining. Therefore titrations of the three antibodies were 
carried out by flow cytometry.  
 
The gating strategy used for analysing CD4+ T cells from PBMCs is shown in Figure 3. 
PBMCs were stained with vital dye and then surface antibodies for the CD3+/CD4+ 
molecules. Firstly, lymphocytes were gated upon on the plot showing side scatter against 
forward scatter of the total CD8-depleted PBMC population (Figure 3A), and live cells 
gated upon within the lymphocyte population (Figure 3B) and finally the CD3+CD4+ T 
cells gated upon from the lymphocyte population (Figure 3C). All subsequent analyses in 
this study were gated in this manner, and further analysed the cells falling within the 
CD3+CD4+ gate. 
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Figure 3 - Gating strategy for analysis of CD4 positive T cells from PBMCs of healthy donors.  A) The gated region 
represents the lymphocyte population. B) The gated region represents live, viable cells that had not bound to the vital dye. 
The viability dye irreversibly labels dead cells and fluoresces within the pacific blue region.  C) The gated region represents 
CD3+CD4 T cells that were contained within the live cell gate shown in B. 
  
 
For the intracellular staining of transcription factors and titrations of the transcription 
factor-specific antibodies, three individual methods/kits for cell fixation and 
permeabilisation were compared to determine the optimal method for use with each 
antibody. The three methods will be referred to as the ‘PFA method’ involving in house 
preparation of all the reagents as described in the materials and methods, the 
‘eBiosciences method’ which utilised a commercialised fixing reagent purchased from 
eBiosciences and the ‘FOXP3 staining kit method’ which  involved fixing/permabilising 
reagents provided in a commercially available kit (see methods).  
 
The results for the FOXP3 antibody used in combination with the three methods are 
shown in Figure 4A. In the top panel, very little staining was observed within the CD4+ T 
cells when fixed/permeabilised using the PFA method. However when the cells were 
fixed and permeabilised using the FOXP3 staining kit method, a discrete population of 
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12.5% of total CD4+ T cells were identifiable as expressing FOXP3 (middle panel), 
which is in line with previous frequencies of FOXP3 positive cells in the blood
38
. 
Although FOXP3 expression was detected in 8.77% of CD4+ T cells using the 
eBioscience method (bottom panel), the positive population was not as discrete as that 
seen using the FOXP3 staining kit, and an overall increase in the MFI of the total CD4+ 
population indicated significant non-specific binding. 
 
Similar to the FOXP3 results, the GATA3 antibody showed very little staining with the 
PFA method (top panel Figure 4B). However, the most discrete population expressing 
GATA3 was observed with the eBiosciences method at 2.21% of the total CD4+ T cell 
population (bottom panel) and a small less defined positive population with the FOXP3 
staining kit at 1.5% (middle panel). 
 
The TBet antibody (Figure 4C) presented with a very small TBet expressing population of 
the total CD4+ T cell population at 0.564% (middle panel) or negative staining (bottom 
panel) with the FOXP3 staining kit and eBiosciences methods respectively. Positive TBet 
staining was observed with the PFA method (top panel) with 8.17% of the total CD4+ T 
cell population detected as expressing TBet. However, even after this optimisation, 
staining was weak and was unlikely to reflect the true percentage of TBet positive 
populations which was reported to be 20% of  total CD4+ T cells
39
. The TBet antibody is 
available on different fluorochromes and was tested conjugated to PE - which is reported 
to be a brighter fluorochrome (BD Biosciences Fluorochrome laser reference). The results 
yielded a larger more defined TBet expressing CD4+ T cell population (data not shown) 
however, as the MHC II tetramers are on PE, these two antibodies could not be used in 
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combination. Therefore, the combination of the TBet antibody conjugated to PerCP-Cy5.5 
and the PFA protocol was optimal within this investigation.  
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Figure 4 - Optimisation of the FOXP3, GATA3 and TBet intracellular cytokine antibodies using the three intracellular 
staining methods for the optimisation of the intracellular staining protocols. A) Dot plots of the FOXP3 antibody using 
all three intracellular methods. FOXP3 positive CD4 cells are within Q2. The IgG control and FOXP3 antibodies were used 
at 20µl. The CD4+FOXP3+ cells were gated upon as described in Figure 3) Dot plots of the GATA3 antibody. The IgG and 
GATA3  antibodies were used at 20µl. The GATA3 antibody is also conjugated to FITC. C) Dot plots of the TBet antibody. 
The IgG and TBet antibodies were used at 1.25µl. The TBet antibody is conjugated to PerCP-Cy5.5. Note that all dot plots 
are from a minimum of 30 000 events. The CD4+ T cells were gated upon as described in Figure 3 and displayed is CD4+ T 
cells vs. transcription factor. The left hand panels show the IgG isotype controls and the right hand panels the transcription 
factor. 
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After selecting the optimal protocol for the three transcription factor-specific antibodies, each 
was then titrated with their respective method. The FOXP3 titration data is shown as an 
example where the volumes used per test ranged from 2.5-40μl (Figure 5). The optimal 
volume of each antibody was selected based on the largest positive population and no 
unspecific binding (i.e. the entire population shifted to the right). As shown for FOXP3 there 
were increasing positive populations: 1.76%, 3.24%, 5.68%, 36% and 77.9% for the volumes 
2.5-40µl respectively (Figure 5B). However, the volume of 40µl produced a non-specific 
binding shift (increase in MFI) of the entire CD4+ T cell population. Therefore a volume of 
20µl was selected for the FOXP3 antibody as it provided the largest and most discrete 
positive population with no unspecific shifting.  
 
Subsequently, the GATA3 and TBet antibodies were titrated in the same way, however using 
the following volumes (2.5-40μl for GATA3 and 0.5-2.5μl for TBet). With the previous 
criteria, the optimum volumes selected were as follows: 1.25μl for TBet and 20μl for 
GATA3. 
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Figure 5 - The optimal titration of the FOXP3 intracellular antibody using the eBiosciences FOXP3 staining kit. Panel A 
represents the IgG control used at 20µl, the same as the optimal amount for the FOXP3 antibody. Panel B represents the 
titrations series of the FOXP3 antibody at 2.5, 5, 10, 20 and 40µl.  The CD4+ cells were gated as described in Figure 3. The 
FOXP3 positive cells are represented in the Q2 quadrant and were gated upon the CD4+ cells using FITC as described in 
Figure 4.  
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To summarise, the optimal fixation and permeabilisation methods selected for use with the 
TBet, FOXP3 and GATA3 antibodies were the PFA, FOXP3 staining kit from eBiosciences 
and the intracellular fixative (IC) from eBiosciences respectively. Although, further 
optimisation of the TBet staining is required, due to time constraints this was not possible. 
The analysis of the subsets of EBV epitope-specific CD4+ T cells present within CD4+ T cell 
populations in healthy donor peripheral blood was then carried out.  
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3.2 – The percentage of FOXP3, TBet and GATA3 expression amongst EBV epitope-
specific CD4+ T cells in healthy carriers 
 
After optimising the intracellular staining protocol for the transcription factors of the three 
major CD4+ T cell subsets (Th1, Th2 and Tregs) the optimised protocols were used to 
analyse the presence of these subsets within EBV epitope-specific populations in the 
peripheral blood of healthy carriers.  
 
PBMC's were isolated from eight seropositive healthy donors and stained with relevant MHC 
II tetramers (Table 3), as described in the methods, prior to intracellular staining for 
transcription factor expression utilising the relevant protocols as selected in 3.1. 
 
 The EBV MHC II tetramer-specific CD4+ T cells within the CD3+CD4+ T cells (gated as in 
Figure 3) were analysed as shown for two example donors in Figure 6, using MHC II 
tetramers specific for each donor’s individual HLA type. The CD4+/tetramer+ cells were 
discriminated via PE-texas red (CD4) vs. PE (MHC II tetramer).  Donor 1 was MHC DR52b 
and DR7 positive and as shown in the left panel no positive staining was observed in the 
absence of tetramer. The percentage of the total CD4+tetramer+ T cell population observed 
was larger with the LTA lytic tetramer (0.041%) compared to the latent PRS and VYG 
tetramers (0.014% and 0.012% respectively). Donor 2 was also DR52B and DR7 positive and 
the results were similar with a negative result in the absence of tetramer and the latent LTA 
tetramer+  percentage (0.022%) being larger than the latent PRS tetramers (0.168% and 
0.023% respectively). 
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No Tetramer LTA PRS (52) VYG
Lytic Latent
LTA PRS (52) PRS (7)
Tetramer (PE)
CD4 (PE-
Texas Red) LTA
Donor 
1
Donor 
2
 
 
Figure 6 - The gating strategy for the determination of the % of tetramer positive CD4 T cells from the total population of 
CD4 cells. All plots are gated on CD3+CD4+ as described in Figure 3. CD4+/Tetramer+ cells (Q2) were gated upon the total 
CD4 population by PE-texas Red (staining CD4) and PE (staining the tetramers). The far left panel represents the 'no 
tetramer' control for each separate donor. Each subsequent panel represents staining with the indicated tetramer. The top 
panel and bottom panels are from two separate donors and two separate experiments. The gating for the CD4 cells was as 
described in Figure 3. LTA, PRS, SNP and VYG epitopes are as described in Table 3. Note that the PRS (7) and PRS (52) 
epitopes are from the same EBV antigen but are restricted through HLA-DR7 and HLA-DR52b alleles respectively. Each 
dot plot represents a minimum of 1, 000, 000 events for the top panel donor and 600 000 events for the bottom panel donor. 
  
 
 
 
 
The tetramer+ cells falling within the gates shown on Figure 6 were then analysed for 
expression of TBet, GATA3 and FOXP3 antibodies by intracellular staining. The results from 
two donors are shown in Results Figure 7 and 8 showing examples of the staining obtained 
with the antibodies characterising Th1/Th2 and Tregs, within both the total CD4+ T cell pool 
and within MHC II tetramer-staining cells. The results shown for donor 1 (Figure 7) are from 
CD4+ T cells stained with the MHC tetramer presenting the PRS epitope from the EBNA2 
protein (DR7 restricted) or for donor 2 with the PAQ tetramer also from the EBNA2 protein 
(DR17 restricted) (Figure 8).  
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The staining for donor 1 indicated that the % of TBet+ CD4+ T cells was the largest positive 
population at 16.1% of the total CD4+tetramer+ T cell population (Figure 7 bottom panel). 
This was followed by 8.65% for the FOXP3 expressing CD4+tetramer+ T cells (top panel) 
and a negative GATA3 staining (middle panel). The staining for donor 2 opposed the FOXP3 
results for donor 1 by presenting with a negative FOXP3 response (Figure 8). However, the 
staining also indicated TBet expressing CD4+tetramer+ T cells (8.1%) and a negative 
GATA3 staining. 
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Figure 7 - % of tetramer positive cells within a healthy donor. The far left column represents the no TF antibody and no 
tetramer control. The second column represents the TF antibody+ and tetramer negative control. The third column represents 
the tetramer+ and TF antibody negative samples. The final column represents the tetramer+/ TF antibody+ cells. The gate 
representing the tetramer+ and TF+ population was set as described in Figure 6. The PRS epitope are as described in Table 
3. The top panel represents the FOXP3 responses, the middle panel the GATA3 responses and the bottom panel the TBet 
responses. All dot plots are from one individual experiment and one donor. 
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Figure 8 - % of tetramer positive cells within a second healthy donor. Results in this figure were analysed as for Figure 5 
but with a separate donor and the PAQ epitope as described in Table 3.  
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Overall, the results did indicate the presence of virus specific TBet expressing CD4+ T cells. 
However, the overall results obtained for GATA3 and TBet expression in the total CD4+ T 
cell populations of the 8 healthy donors (Appendix) were not as high as was expected based 
upon previous literature and the expected number of cells of those subsets
31; 37
. It has been 
reported that 20% of the total CD4+ T cell response within healthy adults (aged 25-50) are 
Th1 cells
39
. Thus the weak staining obtained with the TBet and GATA3 antibodies was likely 
underestimating the % of Th1 and Th2 cells present in the MHC II  tetramer positive cells, 
from this point on, the donors were then screened for EBV-specific CD4+tetramer+ T cells 
expressing FOXP3 only. The summary of the FOXP3 staining detected in the total and MHC 
II tetramer+ CD4+ T cells from eight healthy donors is provided in Figure 9A/B.  
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Figure 9 - Column graphs of the % of tetramer positive cells and transcription factor positive cells within all healthy 
donors. A) The Total CD4 population gate represents the total % of cells expressing FOXP3 as described in Figure 4. The 
tetramer positive cells represent the % of TF+ CD4+ T cells as described in Figure 6. The % of EBV-specific FOXP3+  
CD4+ T cells for each epitope rested in this investigation.  
 
 
  
Tregs have been described as comprising 2-5% of the total CD4+ T cells within healthy 
donor PBMCs. The results in this investigation demonstrated that the percentage of FOXP3 
expressing cells within the total CD4+ T cell population of healthy donors falls within a 
remarkably small range (2-5.18%) which is in line with the published data (Figure 9A). The 
data summarised in Figure 9A, indicate that there are in fact EBV-specific CD4+ T cells 
expressing FOXP3, to the epitopes tested in this investigation from both the lytic and latent 
phases. The percentages of FOXP3 expressing CD4+tetramer+ T cell populations are spread 
with one high value (18.5%) and one negative response. The EBV-specific FOXP3 
expressing CD4+ T cells did not appear to be focused towards either the latent or lytic 
antigens (Figure 9B) with the mean percentages being rather similar (excluding epitopes 
tested once). Furthermore there does not appear to be one epitope in particular that elicits a 
large EBV-specific FOXP3 expressing CD4+ T cell population. There was one high % 
(18.5%) of EBV-specific CD4+ T cells expressing FOXP3 within the SRD positive 
population but this epitope was tested once only.  
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 3.3 – The percentage of Th1, Th2 and Tregs responding to EBV epitopes in IM patients 
 
After testing a panel of healthy donors for EBV-specific FOXP3+ CD4+ T cells to epitopes 
described in table 3, preliminarily experiments were conducted to investigate the presence of 
FOXP3+ expressing EBV-specific CD4+ T cells during primary virus infection using 
previously collected peripheral blood samples from two IM patients (Figure 10 and 11).  
  
  
 
  
Figure 10 - Preliminary intracellular staining data for IM patient 232. Panel A shows the flow cytometry dot plots for the 
lytic VKL tetramer positive CD4 cells. Panel B shows the flow cytometry dot plots for the latent PAQ tetramer positive CD4 
cells. The transcription factor positive cells were gated on as described in Figure 4. The tetramer positive cells were gated on 
as described in Figure 6. The tetramer and transcription factor positive cells were gated upon as described in Figure 7. The 
population in the Tetramer positive cell panel represents the population gated in the Total CD4 + Tetramer panel. Note that 
this figure represents data from one IM donor and one experiment. 
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Figure 11 - Preliminary intracellular staining data for IM patient 161. Panel A shows the flow cytometry dot plots for the 
lytic LTA tetramer positive CD4 cells. Panel B shows the flow cytometry dot plots for the latent PRS tetramer positive CD4 
cells. The transcription factor positive cells were gated on as described in Figure 4. The tetramer positive cells were gated on 
as described in Figure 6. The tetramer and transcription factor positive cells were gated upon as described in Figure 7. The 
population in the Tetramer positive cell panel represents the population gated in the Total CD4 + Tetramer panel. Note that 
this figure represents data from one IM donor and one experiment. 
  
 
 
 
Although the data is preliminary, it is clear that in the two IM donors analysed in Figure 10 
and 11 whilst FOXP3+ expressing cells could be found within the total CD4+ T cell 
population (second column Figure 10 and 11), all the epitope-specific CD4+ T cells from 
both donors were FOXP3 negative (fourth column Figure 10 and 11). This contrasts with the 
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healthy donor data where 7 out of 8 donors appeared to have a range of EBV-specific CD4+ 
T cells expressing FOXP3 present within the tetramer positive populations of the epitopes 
tested (Figure 7, 8 and 9). The total FOXP3 expressing CD4+ T cells appear to be diminished 
within IM patient 232 (Figure 10) as compared to the two healthy donors (Figure 7 and 8). 
The investigation into more IM patients will provide a clearer picture whether a reduction of 
EBV-specific FOXP3 positive cells is a phenomenon of IM, or a feature of the two patients 
analysed in the present project.  
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CHAPTER 4 - DISCUSSION 
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The CD8+ T cell response to EBV has been well-documented over several decades
3
. The 
EBV-specific CD4+ T cell response has been far less well characterised at the single cell 
level as a result of the lack of tools for the analysis of virus-specific CD4+ T cells. Recent 
advances in knowledge of proteins and epitopes targeted by the CD4+ T cell immune system 
have facilitated the development of MHC II tetramers
29
. These have for the first time, enabled 
the visualisation of changes, within healthy donors, of the EBV-specific CD4+ T cell 
response from primary infection to long term carriage
11
. CD4+ T cells are clearly of 
importance in controlling virus infection since patients with EBV-induced PTLD who receive 
therapeutic EBV-specific T cells have been shown to achieve greater clinical success if those 
preparations contains >5% CD4+ T cells
25
. Further understanding the characteristics of CD4+ 
T cells that are important for the control of EBV in healthy individuals may define what is 
important for including within therapeutic preparations to enhance T cell-based treatments for 
EBV malignancies. Complicating the matter, the CD4+ immune response comprises multiple 
subsets with separate functions and cytokine production (Figure 2)
19
. The results from this 
investigation may represent a model platform for increasing what is known about the CD4+ T 
cell response to viruses other than EBV. 
 
 
4.1 – Optimisation of the ICS for nuclear transcription factors 
 
In order to optimise staining, three cell fixing/permeabilising protocols for each antibody - 
‘PFA’, ‘FOXP3 staining kit’ and ‘eBiosciences’ were investigated for the intracellular 
staining of three transcription factor-specific antibodies TBet GATA3 and FOXP3. 
Surprisingly, optimal intracellular staining was detected with separate protocols – TBet with 
the PFA, GATA3 with the eBiosciences and FOXP3 with the FOXP3 staining kit. However, 
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throughout the investigation the TBet staining was very weak (8.1% Figure 4C) based on 
results obtained previously in the literature, in which ~20% of the total CD4+ T cell pool are 
reported to express TBet
39
. GATA3 has been demonstrated within our lab to be expressed in 
low % of the total CD4+ T cell pool (unpublished data); however the staining obtained in this 
investigation (2.31% Figure 4B) was lower still. Due to time restrictions it was not possible 
to further optimise ICS for TBet and GATA3. However, the optimisation of FOXP3 staining 
was of greater success. The % of FOXP3 expressing CD4+ T cells obtained was in the range 
of 5-12% which is in line with previous literature of 5-10%
38
. The difference in staining 
obtained was unexpected given that all three are specific for nuclear transcription factors. 
This may be a result of the differing affinities of the antibodies. 
 
4.2 - MHC II tetramer staining within healthy donors 
 
Having optimised intracellular staining for transcription factors within total CD4+ T cells, 
these protocols were combined with surface staining using MHC II tetramers to analyse the 
CD4+ T cell subsets present within EBV-specific populations.  
 
The frequencies of tetramer positive CD4+ T cells detected within the blood of healthy 
donors in this investigation specific for epitopes PRS (0.106%, 0.076% and 0.044% (Figure 
7) and PAQ (0.026%, 0.027% and 0.056% Figure 8) were within the range as previously 
published for the same epitopes
11
, demonstrating successful combination of the MHC class II 
staining with the transcription factor staining.  
 
Similar to the optimisation experiments, the range of frequencies of the total CD4+ T cell 
population  expressing TBet was 0.56 to 7.26% (Appendix Table 2 and 3). Unexpectedly, the 
percentage of TBet expressing CD4+tetramer+ cells detected was higher, and comparable to 
the 20% previously published
39
. For example 24.1% for PRS-specific cells (restricted through 
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DR52b), 23.5% for LTA and 16.1% and 14.7% for PRS (restricted through DR7) (Table A1 
and A2). However these percentages may be inaccurate due to the low numbers of tetramer-
positive cells involved in the analysis and low intensity of the TBet staining. For the GATA3 
staining, the % of the total CD4+ T cell population expressing this TF ranged from 0.8 to 
2.21% (Table A3 and A4) and the CD4+tetramer+ cells from 1.67 to 11.1% (Table A1 and 
A2) again similar to the frequencies seen in the optimisation experiments. 
 
From previous literature it was expected to find that the majority of responses within healthy 
donors would be of the Th1 response
30; 31
. Bickham et al. detected IFN-γ producing CD4+ T 
cell responses to the EBNA1 protein in 18 /19 healthy donors. Leen et al. identified Th1 
responses to the EBNA1, EBNA3C, LMP1 and LMP2 proteins with decreasing frequencies. 
Given the limitations of the TBet and GATA3, and the discrepancies seen with the expected 
frequency of TBet positive CD4+ T cells detected, the remainder of the analyses concentrated 
on determining the presence of FOXP3 expressing CD4+tetramer+ T cells only.  
 
No systematic study of the presence of epitope specific FOXP3 expressing cells whether in 
healthy or IM donors, has yet been carried out.  FOXP3 is a forked helix transcription factor 
that is very closely associated with the development of Treg CD4+ T cells
20
. This subset of 
CD4+ T cells has previously been shown, within an experimental setting, to control the 
proliferation of viral specific CD4+/CD8+ T cells generated from HIV, HCV and HBV 
infections
40; 41; 42
. This establishes them as key components of the development and 
maintenance of viral chronic infections. The manipulation of Tregs may represent a potential 
mechanism of controlling viral infections.  
 
Overall in this study, in 8 donors, a mean frequency of 9.11% FOXP3-expressing cells within 
MHC II tetramer+ cells was detected. The range had a much larger spread than that of the 
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total CD4+ T cell population expressing FOXP3 (Figure 9A) from 4.17% to 16.7% and was 
in line with published results
43
. The total CD4+ T cell population remained~5% expressing 
FOXP3. This could be a result of different characteristics of T cells specific for the different 
epitopes or intrinsic properties of the proteins the epitopes are derived from, but is more 
likely due to the fact it is hard to define the true % of the FOXP3 expressing CD4+ tetramer+ 
T cells as this is limited by the lower number of tetramer positive cells within the total CD4+ 
T cell population. Despite this limitation, it is clear that FOXP3-expressing EBV epitope-
specific CD4+ T cells are present in the blood of healthy EBV carriers. 
 
 A limited number of previous studies have attempted to analyse the presence of Tregs in the 
blood of healthy donors. A study by Voo et al, identified IL-10 production by CD4+ T cell 
lines specific for an epitope within the EBNA 1 protein
44
. These lines were also able to 
suppress CD4+/CD8+ T cells,  indicating the possibility that some EBV epitopes could 
induce a Treg response
44
. Previous studies to detect the presence of FOXP3+ Treg cells 
against the LMP1 protein have also been carried out within the persistent infection setting
45
. 
The study utilised the PRG epitope from the LMP1 protein to stimulate PBMCs from 
seropositive patients. They found high production of IL-10 by CD4+ T cells specific for the 
PRG epitope within seropositive patients able to suppress IFN-γ production. 
 
4.3 – MHC II tetramer staining within IM patients 
 
The final part of this study involved preliminary analysis of the presence of FOXP3-
expressing EBV-specific CD4+ T cells in the blood of two IM patients. The % of tetramer 
positive CD4+ T cells detected within both IM donors in this investigation (Figure 9) for 
epitopes VKL ( 0.682%) and PAQ ( 0.98%)  in IM232 and for epitopes LTA (0.1% ) and 
PRS (0.186%) in IM161 were in a similar range to previously published frequencies for these 
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epitopes in primary infection
11
. The study by Long et al. also observed higher staining with 
the latent than lytic epitopes and the % of CD4+ T cells that stained with the relevant 
tetramer. Interestingly, within both IM donors, a lack of EBV-specific CD4+ T cells 
expressing FOXP3 was observed within the tetramer positive population (Figure 10 and 11). 
 
A further  intriguing finding within this investigation was a decrease in the  percentage of the 
total CD4+ T cell population that expressed FOXP3 within IM donor 232 compared to the 
healthy donors (Figure 7 and 8). If EBV-specific CD4+ T cells found in IM donors truly do 
not contain any FOXP3 positive cells, then it could be speculated that the sum of the 
expanded CD4+ T cell responses seen during IM may be large enough to alter the overall 
percentage of FOXP3-expressing CD4+ T cells within the peripheral blood.  This could 
account for the smaller frequency of FOXP3-positive cells detected within the total CD4+ 
population of IM232 rather than an actual deduction in the Treg population.  
 
It must be stressed that these results are based on the analysis of two EBV epitope-specific 
populations in two donors, and further analyses are required to confirm this finding. 
However, the results are backed up by two previous studies
46; 47
. Whilst neither study was 
able to analyse Tregs at an epitope level as in the present study, they both demonstrated that 
Tregs were decreased within the blood of IM patients as compared to non IM patients. 
Furthermore, the same frequencies were reflected in the tonsillar distribution of these cells 
demonstrating the decrease in peripheral Tregs could therefore not be accounted for by an 
accumulation within the tonsils (the site of primary EBV infection). The results of this project 
are supported by the second study by
47
 where the authors describe a large Th1 response 
during the acute phase of disease with recovery being associated with the development of 
regulatory responses in four IM patients. 
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The results presented here have expanded upon previous studies by carrying out a systematic 
analysis of CD4+ T cells specific for peptides from a range of lytic and latent EBV proteins 
within 8 healthy and 2 IM patients using MHC II technology. The data indicate that EBV-
specific FOXP3+ Treg cells may be present within healthy donors and absent in IM patients 
where T cell control of the virus is principally lost. This finding suggests a possible role for 
Tregs, within the context of primary EBV infection, in controlling the proliferation of EBV 
specific CD4+/ CD8+ T cells. Tregs have been identified as important in the suppression of 
over robust immune responses from both CD4+/CD8+ T cells, it may be logical to speculate 
that the lack of Tregs during IM might contribute to significant expansions of both these T 
cell subsets seen.  
  
This investigation may provide us with a model hypothesis for the development of IM and 
indicate why some patients of similar ages develop IM and not others. It is possible that 
Tregs become activated early during acute primary infection and block the proliferative 
expansion of CD8+/CD4+ T cells that are characteristically seen in IM. The failure of this 
protective Treg response may play a part in combination with other genetic factors known to 
be linked with symptomatic infection such as NK cells and HLA type
48; 49
 to the progression 
to IM.  
 
To gain further insight into the EBV-specific CD4+ T cell subsets, cytokine staining should 
be combined with ICS for the nuclear transcription factors. CD4+ T cell subsets are 
particularly fluid and pleotropic and as a consequence some cells express more than one 
master regulator and thus express multiple combinations of cytokines. This combination 
could definitively aid the definition of the subsets present. 
 
 
 54 
4.4 - Future Research 
 
One of the objectives of this project was to understand the CD4+ T cell subsets involved in 
the control of EBV in healthy donors in order to facilitate the design of future 
immunotherapies for patients with EBV-associated disease. Although effective, around 50% 
of the EBV-associated malignancy patients treated with chemotherapy develop serious side 
effects, tumour relapse or secondary tumours [reviewed in
50
]. Each year, ~200 000 cases 
worldwide of EBV positive malignancies are diagnosed (Table 6). The reduction in cases 
arising from EBV associated malignancies via the use of an EBV prophylactive or 
therapeutic vaccine would undoubtedly improve public health and economic infrastructure.  
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Malignancy: Cell of Origin % Associated 
with EBV 
Cases associated 
with EBV: 
Burkitt Lymphoma: 
Developed 
Undeveloped 
B cell Undeveloped: 
AIDS 30-40% 
African 90% 
Developed: 
Sporadic 10-170% 
6700: 
100 
6600 
Gastric Carcinoma Epithelial cell 10% 84 050 
Hodgkin Lymphoma B cell 40-80% 28 600 
Nasopharyngeal 
Lymphoma 
Squamous 
epithelial cell 
90% 78 100 
Total:   196, 450 
Table 7 – The annual estimated new cases of EBV associated malignancies worldwide50 
 
Clarification of the role of CD4+ T cell subsets in the control of EBV by identifying those 
peptides which stimulate Th1, Th2 or Treg responses during IM could facilitate opportunities 
for the manipulation of early EBV infection. Similarly, further understanding the 
characteristics of the CD4+ T cells present in healthy donors might help to direct future 
therapies to target epitopes with the greatest potential for controlling EBV patients with 
EBV-associated disease 
 
4.4 – Final conclusion 
 
To conclude the clarification of the range of the CD4+ T cell subsets responding to EBV 
during primary vs. persistent infection will provide opportunities to develop new therapies 
directed towards EBV associated malignancies. The success of therapy directed towards EBV 
associated malignancies may be enhanced by the manipulation of the immune response 
towards the ratios of T cell subsets seen in healthy carriers.  
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Table A1 – Raw values of the % of CD4 T cells that are tetramer positive and transcription factor positive 
responding to the latent epitopes 
 
 
 
 
 
 
 
 
 
Table A2 – Raw values of the % of CD4 T cells that are both tetramer and transcription factor positive responding to 
the lytic epitopes 
 
 
 
 
Donor; % Tetramer/TF positive CD4 cells 
PAQ PRS 7 PRS 52 SNP VYG 
Latent Tbet Foxp3 Gata3 TBet Foxp3 Gata3 Tbet Foxp3 Gata3 TBet Foxp3 Gata3 TBet Foxp3 Gata3 
1 - - - - 9.6 - - - - - - - - 10.6 - 
2 - - - - - - 24.1 12.2 0 18.7 7.14 0 - - - 
3 - - - - - - 5.74 9.11 7.29 17.5 12.5 1.75 - - - 
4 - - - - - - - - - 2.91 4.23 1.26 - - - 
5 8.1 0 0 - - - - - - - - - - - - 
6 - - - 0 16.7 5.26 4.94 12.21 3.41 - - - 0 9.71 1.67 
7 - - - 16.1 8.65 0 - - - - - - 0 5.67 11.1 
8 - - - 14.7 4.17 6.67 2.08 9.59 6.42 - - - - - - 
Mean 
%: 
8.1 0 0 10.27 9.78 3.9767 9.215 10.778 5.7067 13.04 7.9567 1.0033 0 7.69 6.385 
Donor; % CD4 tetramer/TF positive  CD4 cells 
LTA VKL SRD 
Lytic TBet Foxp3 Gata3 TBet Foxp3 Gata3 TBet Foxp3 Gata3 
1 - - - - - - - - - 
2 23.5 8.55 1.72 - - - - - - 
3 - - - - - - - - - 
4 - - - - - - - - - 
5 - - - 10.5 4.17 1.89 - - - 
6 3.03 9.22 3.57 - - - - - - 
7 - - - - - - 0 18.5 6.67 
8 6.67 9.59 5.8 - - - - - - 
Mean 
%: 
11.07 9.12 3.6967 10.5 4.17 1.89 0 18.5 6.67 
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Table A3 – Raw values of the % of CD4 T cells expressing the relevant transcription factor 
 
Donor; % CD4/TF+ Cells (Total CD4) 
LTA VKL SRD 
Lytic TBet Foxp3 Gata3 TBet Foxp3 Gata3 TBet Foxp3 Gata3 
1 - - - - - - - - - 
2 0.696 4.63 1.06 - - - - - - 
3 - - - - - - - - - 
4 - - - - - - - - - 
5 - - - 1.16 4.26 1.29 - - - 
6 2.51 4.46 1.72 - - - - - - 
7 - - - - - - 1.07 4.31 1.02 
8 1.45 3.54 1.02 - - - - - - 
Mean 
%: 
1.552 4.21 1.2667 1.16 4.26 1.29 1.07 4.31 1.02 
Table A4 – Raw values of the % of CD4 T cells expressing the relevant transcription factor 
 
 
 
 
 
Donor; % CD4/TF+ Cells (Total CD4) 
PAQ PRS 7 PRS 52 SNP VYG 
Latent TBet Foxp3 Gata3 TBet Foxp3 Gata3 Tbet Foxp3 Gata3 TBet Foxp3 Gata3 TBet Foxp3 Gata3 
1 - - - - 2.03 - - - - - - - - 2 - 
2 - - - - - - 0.76 4.85 1.2 0.573 3.95 1.28 - - - 
3 - - - - - - 0.517 4.54 1.24 0.935 4.24 1.24 - - - 
4 - - - - - - - - - 7.26 3 2.21 - - - 
5 1.01 4.17 1.58 - - - - - - - - - - - - 
6 - - - 2.33 4.1 1.42 4.6 5.02 1.42 - - - 2.85 4.78 1.46 
7 - - - 0.889 5.18 1.36 - - - - - - 0.562 4.31 0.797 
8 - - - 2.18 3.85 0.869 1.76 3.64 0.694 - - - - - - 
Mean 
%: 
1.01 4.17 1.58 1.79967 4.3767 1.2163 1.909 4.5125 1.1385 2.9227 3.73 1.5767 1.706 4.545 1.1285 
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Abstract 
 
In CMV-seropositive elderly donors virus-specific CD8+ T cells against the pp65 and 
IE-1 proteins can occupy up to 40% of the total CD8+ T cell pool. CMV encodes for 
several immunomodulatory proteins that interfere with the MHC class I antigen 
presenting pathway. Studies using an immunevasion-deleted virus strain (RV798) 
revealed a large proportion of CMV-specific T cell responses are evaded by cells 
infected with WT virus, but are primed in vivo. This study undertook the first 
functional and phenotypical characterisation of CD8+ T cells in young and elderly 
donors responding to CMV-derived epitopes identified using the deletion mutant. 
These CD8+ T cells seem to accumulate within the elderly reaching up to 32%, 
against a HLA-C restricted epitope, of the total CD8+ T cell pool producing IFN-γ, 
TNF-α and little IL-2. The CD8+ T cells were CD45RA+/CD57+/CD28-/CCR7- and 
therefore of the EMRA compartment. In vitro they recognised their antigen in the 
context of RV798 infection, but not wild type (WT) infection. In summary the CD8+ 
T cells specific for the ‘protected’ antigens studied here display very similar 
characteristics compared to previously studied CMV-specific CD8+ T cells. What is 
currently unclear is the role in vivo they play in controlling the virus.  
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1.1 – Cytomegalovirus 
Cytomegalovirus (CMV) is a member of the β-herpesviruses, a sub family of the 
Herpesviridae (Reviewed
1; 2
). It is a large double stranded DNA virus whose genome 
is enclosed by a capsid surrounded by a tegument layer and enveloped by a bilipid 
membrane containing glycoprotein complexes. The hCMV genome is ~230 Kb of 
DNA in size encoding for >160 proteins. Around 60% of the adult population are 
infected with this virus (up to 90% depending upon geographic location and 
socioeconomic status) with primary infection usually being asymptomatic. CMV is 
able to infect a wide range of host cells such as: endothelial cells, epithelial cells, 
fibroblasts and dendritic cells
3
. Persistence is established in CD34+ hematopoietic 
progenitor cells 
4
 and maintained in the myeloid lineage. Reactivation of the virus is 
very closely linked with the differentiation of dendritic cells (DCs) and their 
activation status
5
. Transmission into naïve hosts occurs via bodily fluids such as 
saliva, urine and also via breastfeeding or intrauterine. In immunocompetent 
individuals this is kept under control by the immune system. However, this virus 
causes serious and even fatal disease and organ damage within the 
immunocompromised host (such as AIDS or transplant patients and during congenital 
infection) as a result of uncontrolled viral replication. The use of the murine model 
and studies within humans have identified T cell immunity, in particular CD8+ T 
cells, as the critical component in controlling CMV infection, limiting virus spread 
and reducing clinical manifestations
1
. Even though infection is generally 
asymptomatic in immune competent individuals, hCMV is now increasingly being 
accepted as a major contributor to the development of senescence of the immune 
11 
 
system
6
, poor responses to viral vaccines such the influenza vaccine 
7
 and the 
development of cardiovascular diseases
8
. 
 
1.2 – Immunity to CMV 
Both the innate and adaptive arms of the host immune system play a recognised role 
in controlling CMV dissemination and replication. These include type I interferons 
produced by dendritic cells and macrophages which leads to the activation of Natural 
killer (NK) cells
9
, production of neutralising antibodies
10
 and both CD4+/CD8+ T 
cells 
11
. The T cell mediated immune response to hCMV seems to play a major role in 
the control of the virus as their loss due to immune suppression frequently leads to 
viral reactivation
12
.  
 
All of the hCMV encoded proteins are potential targets for the CMV-specific T cell 
response. The most extensive study of the CMV-specific T cell response to date was 
done by Sylwester et al, which involved the analysis of antigen-specific T cell 
activation using 213 ORFs encoded by the hCMV genome. This for the first time 
provided a global picture of the virus-specific T cell responses and an idea of the 
extent to which it occupies the overall peripheral T cell pool
13
. Of these 213 ORFs 
screened, a total of 151 ORFs induced T cell responses by either CD4+ or CD8+ T 
cells or both as measured by IFN-γ production. The average total CD8+ T cell 
responses to CMV was 7.6%, with each donor recognising an average of 21 ORFs.  
 
12 
 
Despite the large number of potential antigenic targets for the CD8+ response, most 
studies to date have focused on two immunodominant proteins namely IE-1, as it is 
one of the first proteins expressed in the virus life cycle, and pp65, the major 
tegument protein which comprises a large part of the virion. There have been recent 
development of efficient and more sensitive methods, such as MHC class I (MHC I) 
tetramer technology, the enumeration of ex vivo cytokine responses post-stimulation 
with overlapping peptides and ‘Enzyme-linked immunospot assays’ (ELISPOT). 
These have allowed the direct detection and a more detailed study of antigen-specific 
CD8+ T cells. Thus, knowledge regarding the breadth of the hCMV-specific CD8+ T 
cell response has increased considerably.  
 
It is now known that hCMV infection occupies a large percentage of the peripheral T 
cell pool
14; 15; 16
 and that this expansion accumulates substantially with age
17
. The 
study by Vescovini et al. demonstrated that the expansion of CMV-specific Th1 like 
CD8+ T cells is further amplified within the extremely elderly (90-100 years). Within 
healthy middle aged patients CMV infection can occupy up to 40% of the total T cell 
pool compared to 2-4% within younger patients. This accumulation termed ‘memory 
inflation’15 has been most extensively demonstrated within murine models of CMV 
infection
2
. Utilising this model T cells specific for certain epitopes have been 
demonstrated to increase with time and stabilise at high frequencies – known as 
‘inflationary epitopes’ (e.g. M38 and IE3 proteins). Other epitopes have been shown 
to elicit small responses that remain so over time – known as ‘stable epitopes’ (e.g. 
M45 and M57 proteins)
16
.  It is currently not very clear whether the same distinction 
can be made in humans between stable and inflationary epitopes.     
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The responses to CMV epitopes have been shown within both mice and humans to 
have a characteristic phenotype which is marked by the expression of CD45RA and 
CD57 and the loss of CD28 and CCR7 expression. It is difficult to analyse the 
primary response to CMV as the time point of natural infection is hard to detect due to 
the asymptomatic nature of primary infection. A study by Van de Berg et al. utilised 
CMV negative renal transplant recipients to monitor their first encounter with the 
virus and phenotypically characterise the responding T cells overtime
8
. A change in 
surface phenotype from CD45RA
-
CD27
+
CCR7
- 
(central memory) to the loss of 
CD28/CD27 and the regaining of the naïve isoform CD45A (revertant memory) was 
observed.  
 
As CMV-specific CD8+ T cells lack the expression of the co-stimulatory molecules 
CD27 and CD28 they produce reduced levels of IL-2 and have previously been thought 
to be dysfunctional
18
. Khan et al. showed that 90% of CMV-specific CD8+ T cells 
within the elderly did not express CD69, CD38 or HLA-DR which are characteristic of 
activated T cells but were perforin positive and therefore cytotoxic
19
. As these CMV-
specific T cells still express significant amounts of effector molecules, others have 
hypothesised that these cells represent ‘late stage effector cell’ rather than being 
dysfunctional. Khan et al. also demonstrated that within elderly patients, there was a 
marked 32% increase in oligoclonality of the CMV-specific expansions
19
. The 
oligoclonality has been proposed to be the result of repeated antigen exposure throughout 
the patient’s life time. Further supporting the functionality of these expansions, CD8+ T 
cells expressing IFN-γ and TNF-α were largely increased within responses to the CMV 
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protein pp65
20
. It is now generally accepted that these inflated CMV-specific CD8+ T 
cell responses are extensively differentiated but retain their functional capabilities
8; 16; 19; 
20; 21
.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Memory inflation has been hypothesised to restrict the naive CD8+ pools and 
consequently impair the inability of individuals to mount a sufficient primary adaptive 
response to new antigens. CMV-seropositivity has been correlated with inefficient 
responses to the influenza vaccine
7
. Furthermore, the accumulation of CD57
+
/CD28
- 
CD8+ T cells has been associated as one of the major indicators of immune 
senescence within the elderly and this in combination with CMV-seropositivity has 
been identified as an ‘Immune Risk Phenotype’ (IRP) that has been linked to 
premature death with patients >80 years of age. It has been further hypothesised that 
the large number of cytotoxic CD8+ T cells within seropositive individuals can 
enhance the severity of vascular diseases for example atherosclerosis (discussed in
8
).  
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1.3 CMV mediated immune evasion 
CMV is not cleared from the host but persists for life. Therefore a fine balance 
between the virus and host has evolved over millions of years. Despite being 
recognised by the immune system, CMV has developed multiple mechanisms to 
evade both innate and adaptive recognition
22
.  
One of the main strategies of CMV to evade innate immunity is to avoid activation of 
NK cells. As numerous mechanisms work to down-regulate MHC I and II molecules 
from the surface this would lead to NK cell activation based on the missing-self 
theory. Ways the virus employs to circumvent this include expression of MHC I 
homologues like UL18
23
 on the surface of infected cells or binding of ligands of 
NKG2D – an activating NK cell receptor – by UL16 to retain them intracellularly24. 
Additionally, hCMV encodes an IL-10 homologue that has been reported to lead to a 
long term decrease in the pools of NK cells allowing the virus to establish its 
persistent infection
25
. 
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Figure 1 – Immunevasion mechanisms of the US2-US11 genes encoded by hCMV. Adapted from1. The US 
genes are indicated by red rods or in the case of USE a red circle. MHC I heavy chains are indicated in dark 
purple. TAP1and TAP2 gene products are indicated in light purple. 
 
However, best understood to date is CMV immunevasion of CD8+ T cell recognition 
of infected cells. Cells infected with hCMV have down regulated levels of ‘Major 
Histocompatibility Class I’ (MHC I) as a consequence of the US2-11 genes encoding 
for immunosubversive proteins. The US2-US11 gene products act in concert to down-
regulate MHC I from the cell surface and to prevent the generation of CMV peptide 
loaded complexes (Figure 1). The overall effect is to limit presentation of viral 
antigens to the CD8+ T cells (individual functions summarised in Table 1).  
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Antigen Function 
US2 Relocation of MHC I heavy chains from the ER for proteasomal degradation 
US3 Retention of MHC I heavy chains within the ER 
US6 Prevents the translocation of peptides from the cytosol to the ER via TAP 
US11 Relocation of MHC I heavy chains from the ER for proteasomal degradation 
Table 1 – MHC Class I subverting immunoevasins encoded by hCMV22  
 
A CMV-strain deleted for US2-US11termed ‘RV798’26 was used by Paul Moss’ and 
Stanley Riddell’ labs to study T cell responses against virus infected cells. This was 
compared to T cell responses induced by fibroblasts infected with WT strains
27; 28
. 
Results showed that the responses after stimulation with the RV798 strain were up to 
10-fold and 40-fold (Khan and Manley labs respectively) increased compared to those 
with the WT.  
Stan Riddell and colleagues hypothesised that the presence of the US genes 
‘protected’ certain CMV antigens from presentation to the CD8+ T cells during 
natural infection. They then employed the RV798 strain to further analyse CMV-
specific CD8+ T cell responses to proteins from across the hCMV genome
28
. Using 
this CMV strain, Riddell et al. identified new peptide-epitopes derived from a number 
of CMV-encoded proteins, confirming that responses are directed against a broad 
range of antigens expressed in the early and late phases of the virus life cycle (see 
Table 3 Materials and Methods). Their results demonstrate that the down-regulation 
of MHC I affects the recognition of CMV-epitopes by CD8+ T cells within infected 
cells.  
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1.4 Aims 
Based on the study using the CMV-strain RV798 which is deleted of the immune 
evasion proteins, Riddell at al. identified a number of peptide epitopes which are 
‘protected’ from T cell recognition in WT infected cells. Currently very little is 
known about the characteristics of these T cell responses in carriers of CMV. 
Therefore, the aims of the study were as follows: 
 
1. To determine whether CD8+ T cells specific for these peptides can be detected 
in healthy individuals 
 
2. To study whether the magnitude of these responses differs between young and 
older individuals i.e. accumulate with age 
 
3. To characterise peptide specific CD8+ T cells with regard to functionality 
(cytokine production) and phenotype 
 
4. To determine whether T cells specific for these peptides are able to recognise 
processed antigen 
 
5. To phenotypically characterise these CMV-specific CD8+ T cells to assert 
whether they have the same characteristic phenotype as previously described 
for CD8+ expansions to other epitopes 
19 
 
 
6. To address whether these newly identified epitopes are recognised by cognate 
CD8+ T cell clones during WT CMV infection of fibroblasts vs. infection with 
the RV798 mutant virus. 
 
Cryopreserved PBMCs from young and elderly seropositive donors were stimulated 
with the relevant epitopes and the CD8+ T cell responses measured by the detection 
of intracellular IFN-γ, TNF-α and IL-2 production. 
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CHAPTER 2 – MATERIALS AND METHODS 
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Reagent Company 
1X Phosphate Buffered Saline (PBS) Dulba 
4% Para formaldehyde in PBS Sigma 
RPMI 1640 Gibco 
Penicillin/Streptamycin Gibco 
Saponin 4% stock in PBS Sigma 
MACS Buffer (1X PBS, 0.5% BSA, 2mM EDTA) In House 
Fetal Calf Serum (FCS) PAA 
Human Serum (HuS) TCS 
Lymphocyte Separation Media PAA 
MLA144 cells Rabin et al 1981 
Media Components 
Culture media RPMI 1640 
10% FCS 
1% P/S 
T cell media RPMI 1640 
30% MLA 
10% FCS 
1% HuS 
1% P/S 
50U/ml IL-2 
Cloning media RPMI 1640 
10% FCS 
1% HuS 
1% P/S 
ELISA reagents Company 
Anti IFN-γ antibody Thermo Scientific 
Biotinylated anti IFN-γ antibody Thermo Scientific 
ExtraAvidin Peroxidase Sigma 
TMB Rockland 
Blocking Buffer – 1 x PBS, 0.05% TWEEN, 1% BSA In House 
Wash Buffer – 1 x PBS, 0.05% TWEEN In House 
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Antigen Fluorchrome Company Volume/test Clone 
CD3 APC Invitrogen 2 μl S4.1 
CD8 AmCyan BD Biosciences 1 µl SK1 
CD4 PE BD Pharmingen 2 μl RPA-T4 
CD57 PE Biolegend 3 µl HCD57 
CD3 Pacific Blue eBioscence 0.5 μl OKT3 
CCR7 FITC R & D 10 µl 150503 
CD27 FITC BD Pharmingen 2 μl M-T271 
CD4 Pe Cy7 eBioscience 1 μl RPA-T4 
CD8 PerCp-Cy5.5 eBioscience 2 μl RPA-T8 
CD28 PerCP-Cy5.5 BD Biosciences 2 µl L293 
IFN-γ FITC Biolegend 2 μl 4S.B3 
TNF-α Pe Cy7 eBioscience 1 μl MAb11 
IL-2 PE Biolegend 10 μl MQ1-17H12 
Viability Dye Fluorchrome Company Volume/test  
LIVE/DEAD Fixable Dead 
Cell Stain 
Violet 
fluorescent 
reactive dye 
Invitrogen 1µl of 1:100 
dilution  
 
Table 2 – Regents used throughout the investigation 
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Table 3 – HLA restricted CMV epitopes (Stan Riddell – unpublished data). 
 
CMV 
Antigen 
location function CTL Epitope 
HLA Restricting 
Allele 
Kinetics of 
Expression 
UL16162-170 glycoprotein NK cell evasion YPRPPGSGL B0702 E 
UL1712-21 unknown  RPRHCRLEML B0702 E 
UL52349-358 
matrix  or 
tegument 
unknown SPSRDRFVQL B0702 L 
UL69569-578 tegument 
cell-cycle arrest (G1 – 
S) transport of 
unspliced RNA from 
nucleus 
RTDPATLTAY A0101 E/L 
UL105715-723 ? 
proposed  helicase 
activity,    DNA 
replication 
YADPFFLKY A0101 E 
US2365-73 
matrix or 
tegument 
unknown IPHNWFLQV B5101 E 
UL122466-475 IE2 
replication, inhibition 
of apoptosis 
NEGVKAAWSL B4403 IE 
UL56503-511 
matrix or 
tegument 
involved in DNA 
encapsidation 
DARSRIHNV B5101 E 
UL3651-60 
(matrix  or) 
tegument 
inhibitor of caspase 
activity (apoptosis) 
RSALGPFVGK A1101 E 
UL367-21   
TLMAYGCIAIR
AGDF 
B5101 E 
UL3678-88   HPFGFVEGPGF B3501 E 
UL2334-42 tegument unknown WPKDRCLVI B5101 ? 
UL23162-171   RATYRGRLMV Cw1502 ? 
UL28327-335 unknown 
unknown, encodes 
spliced mRNA? 
FRCPRRFCF Cw0702 ? 
UL33120-128  
putative chemokine 
receptor  (G-coupled 
receptor)   --> 
signalling 
SYRSTYMIL Cw0702 E 
UL24120-134 tegument  
YLCCQTRLAFV
GRFV 
Cw1601 E/L 
UL843-11  
suggested role in DNA-
synthesis 
RVDPNLRNR A0301 E 
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2.1 - Preparation of PBMC's from healthy donor blood 
 
15 young donors aged 27 to 59 years and 16 elderly donors from the ‘1000 elders 
cohort’ aged 68  to 86 years were analysed (Appendix Table 7 and 8). Written consent 
was taken.  
‘Peripheral blood mononuclear cells’ (PBMCs) were isolated from whole blood by 
density gradient centrifugation. Seropositive heparinised blood was diluted 1:1 with 
RPMI and layered onto 15ml of Lymphoprep. This was centrifuged at 1800 rpm for 
30 minutes at 22
o
C with the brakes off. Lymphocytes were very carefully aspirated 
off the interface between the lymphoprep and plasma/RPMI and washed with 30ml of 
fresh RPMI to remove ficoll (spun at 2000 rpm for 10 minutes and 22
o
C). Cells were 
washed again in RPMI and resuspended in culture medium (materials) for counting on 
a haemocytometer. The pellet was resuspended in freezing medium containing 10% 
FCS and 1 x 10
6
 cells transferred to a cryovial. Cryovials were kept at -80 overnight 
before transfer into liquid nitrogen for long term storage. 
2. 2 - Peptide stimulation of PBMCs 
To assess T cell responses, peptide stimulations were set up. For this, PBMCs were 
thawed in culture medium, centrifuged at 1600 rpm for 5 minutes and resuspended 
within 1-2ml for counting. 1 x 10
6
 cells per stimulation were used in a total volume of 
500μl culture medium. Relevant peptide was added to the tubes at a final 
concentration of 1μg/ml. 10μl of ‘Staphylococcus enterotoxin B’ (SEB) served as a 
positive control (final concentration 0.2µg/ml) and one tube was left unstimulated 
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(negative control). Brefeldin A (BfA; 10µg/ml final concentration) was added to 
block cytokine secretion. The tubes were incubated at 37
o
C for 6 hours. 
 
2.3 Intracellular cytokine staining 
Following stimulation, PBMCs were stained to detect the production of cytokines by 
activated T cells. PBMCs were washed once in PBS and centrifuged at 2000rpm at 
10
o
C for 5 minutes (all washes were done in 4ml and centrifuged as just described). 
Viability dye (materials) was added and tubes left to incubate for 15 minutes room 
temperature in the dark before one wash in PBS and one wash in MACS buffer. 
Antibodies staining surface molecules were added and tubes incubated for 15 minutes 
at 4
o
C in the dark after which they were washed in MACS buffer. To fix the cells, 4% 
PFA was added, vortexed well and incubated for 15 minutes at room temperature in 
the dark. The PFA was washed off once with MACS buffer followed by 
permebilisation with with 0.5% saponin. After 5 minutes, intracellular antibodies 
were added and left to incubate for 30 minutes at room temperature in the dark. Cells 
were washed with MACS buffer and left at 4
o
C until analysis on the LSR. Data 
analysis was performed using BD FACS Diva analysis software. 
2.4 CD8 T cell cloning 
CD4 depleted PBMC were stimulated with the relevant peptide (final concentration 
1µg/ml) for 3 hours to induce activation and IFN-γ production of specific T cells. 
These were then enriched using an IFN-γ- secretion assay cell enrichment and 
detection kit (Miltenyi Biotec) before limiting dilution cloning. 
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2.4.1 IFN-γ capture assay 
 
After the 3 hour stimulation, cells were washed twice in culture medium. The 
supernatant was removed and the pellet resupsended in 120μl of cold medium and 
30μl of IFN-γ catch reagent added. These were incubated on ice for 5 minutes before 
addition of 10ml warm cloning medium and further 45minutes incubation at 37
o
C 
while rotating. 
Cells were then washed with 15ml cold MACS buffer and centrifuged at 2000 rpm for 
5 minutes at 4
oC. The pellet was resuspended in 120μl MACS buffer. 30μl of anti 
IFN-γ catch reagent conjugated to PE added and left to incubate at 4oC for 10 minutes 
in the dark. 
Following this, cells were washed as before and resuspended in 120μl MACS buffer 
and 30μl of anti PE microbeads added and left to incubate for 20 minutes at 4oC in the 
dark. 
Unbound microbeads were washed off and labelled cells resuspended in 500µl of 
MACS buffer. IFN-γ producing cells were then enriched using a MACS-separator 
according to manufacturer’s instructions. Cells of the positive fraction were collected 
and counted before use in limited dilution cloning. 
 
2.4.2 Limiting Dilution Cloning 
 
PBMCs isolated from Buffy preparations were PHA treated (final concentration 
10µg/ml) for 1 hour before irradiation with 4000 rads – these served as a feeder layer 
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in the cloning procedure. Autologous LCLs were peptide pulsed (with the 
corresponding peptide) for 1 hour at 37
o
C before also being irradiated with 4000 rads 
to prevent proliferation – these served as antigen-presenting cells.  
Per 10 plates, 100ml of cloning mixture (materials) were prepared consisting of: 
 100 x 106 Buffy cells 
 10 x 106 LCLs 
100µl/well were plated out. 
 
For the limiting dilution cloning of cells retrieved in the positive fraction (in section 
2.4.1), 10 plates (96-well round bottom) with 0.3 cells/well and 10 plates with 3 
cells/well were seeded for each specificity. 
The limiting dilution cultures of LCLs and T cells were then ‘fed’ on day 2 with 
100µl/well media (60% MLA, 10% FCS, 1% HuS, 1% P/S and 100U/ml IL-2) and 
left at 37
o
C for 2 weeks.  
2.5 – Assessment of peptide specificity following limiting dilution cloning 
 
2 weeks after cloning ,wells were identified that showed cell expansion and tested for 
peptide specificity. For this, 50µl was taken from the selected wells and co cultured 
with peptide-pulsed or DMSO-pulsed autologous LCL at 37
o
C overnight in duplicate. 
ELISA plates were coated over night with an anti IFN-γ antibody. The following day, 
plates were blocked for 1 hour  with blocking buffer (materials) at room temperature 
then washed three times in wash buffer (materials). 50μl supernatant from the 
overnight co-cultures was added to the relevant wells and left to incubate for 2 hours 
at room temperature. The IFN-γ standard was also added to the wells at this point. A 
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second biotinylated antibody that binds IFN-γ was then added to the wells at 3.75μl 
per plate and left to incubate for 2 hours at room temperature. A 1:2 dilution series of 
IFN-γ starting at 2000pg/ml served as a standard curve. Following six washes in wash 
buffer  a biotinylated anti IFN-γ antibody was added and left to incubate for 1 hour at 
room temperature. After this, plates were washed six times in wash buffer and 50µl of 
peroxidase-conjugated ExtraAvidin (1:1000 in wash buffer) per well for 30 minutes at 
room temperature. This was washed off in wash buffer eight times; TMB substrate 
solution was added and allowed to develop for up to 30 minutes before stopping the 
colour development by the addition of IM hydrochloric acid. Absorbance was 
measured at 450nm. 
Specific clones were transferred to and propagated on 24 well plates for further use 
and cryopreservation.  The clones were maintained in 2ml T cell media (materials) 
with the addition of 1 x 10
6
 PHA treated, irradiated Buffy cells and 1 x 10
5
 peptide 
pulsed, irradiated LCLs.  
 
2.6 – Fibroblast Recognition Assay 
 
1.5 x 10
4
 fibroblasts expressing HLA-A1 per well of a 96 well plate were seeded and 
left to adhere overnight. Fibroblasts were then infected with either the AD169 or 
RV798 strains at an M.O.I. of 0.5 or 0.05 for 48 hours. After 48 hours, RTD and 
YAD-specific CD8+ T cells were added at 10000 cells per well and left overnight. T 
cell recognition was assessed by IFN-γ detection in an ELISA of the supernatant of 
the co-cultures. 
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CHAPTER 3 - RESULTS 
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 3.1 – Titrations of the intracellular cytokine antibodies 
 
The first aim of the study was to identify CD8+ T cells which respond to the 
investigated epitopes by cytokine production. These were detected by flow cytometry 
using intracellular cytokine staining (ICS). For two of the three cytokine-specific 
antibodies, anti-IFN-γ and anti-TNF-α it was necessary to determine the appropriate 
concentration to stain with. For this purpose PBMCs were stimulated with SEB, 
stained with CD8-PerCP-Cy5.5 and decreasing concentrations of the cytokine-
specific antibodies ranging from 5µl (manufacturer’s recommendation) to 0.5µl. 
Results of the antibody titrations are depicted in Figure 2. 
 
For the analysis, single cells were gated on followed by selection of the lymphocytes 
(Figure 2A). The lymphocyte gate was then further analysed for the expression of 
CD8 and production of cytokine (Figure 2B). To calculate the response size of CD8+ 
T cells, the percentage of cytokine producing CD8+ T cells within the total CD8+ T 
cell population was calculated. These are displayed as the percentage of CD8+ T cells 
in Figure 2B and C.  
 
The criteria for selection of the appropriate antibody concentration was the detection 
of a distinct positive population which was on the scale of detection. For the anti-
IFNγ antibody this was achieved with the use of 2µl per test, for anti-TNFα, the 
chosen volume of antibody per test was 1µl (Figure 2B and C). These were used in all 
subsequent experiments. 
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Figure 2 – Titration of cytokine-specific antibodies. A) Gating Strategy. Initially single cells were gated upon. Of 
these, the lymphocyte population was gated using FSC vs. SSC.  Analysed then was the cytokine production (B) 
IFN-γ  or (C) TNF-α of CD8+ T cells with increasing amounts the antibody to be tested Indicated are the 
percentage of the total CD8+ T cells producing cytokine in response to stimulation with SEB.  
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3.2 – Detection of CD8+ T cells specific for CMV-derived epitopes in young 
healthy donors 
The peptide epitopes studied in this project have recently been identified using a 
CMV-strain termed RV798 which is deleted for the immunevasion molecules. To 
date, T cell responses to these epitopes have not been characterised in detail. In the 
first instance, 15 young CMV seropositive donors (aged from to 27-59) were chosen 
to analyse CD8+ T cell responses to these CMV-derived antigens. PBMCs were 
stimulated with peptide epitopes according to HLA-restriction matched with the 
donor’s HLA-type. Details for the donors can be found in the appendix - Table A1. 
Figure 3A demonstrates the gating strategy used throughout the study for the analysis 
of ICS. Single, viable, CD3+ lymphocytes were identified and then analysed for the 
frequency of cytokine producing CD8+ T cells within this population. In all 
subsequent ICS, the CD8+ T cells were gated for in this manner. Example dot plots 
and the percentage of CMV-specific CD8+ T cells responding to a selection of the 
tested epitopes are shown in Figure 3B.  
Examples of four epitope-specific CD8+ T cell responses in young donors are shown 
in Figure 3B. The largest CD8+ T cell responses seen are against the HLA-Cw16 
restricted FRC (2.09% IFN-γ and 2.25% TNF-α) and the HLA-B44 restricted NEG 
(2.31% IFN-γ and 3.98% TNF-α) epitopes. The RTD (0.03% IFN-γ and 0.04% TNF-
α) and YAD (0.16% IFN-γ and 0.27% TNF-α) epitopes (both HLA-A1 restricted) 
elicited the smallest CD8+ T cell responses. These results demonstrate the potential of 
these peptides to induce CD8+ T cell responses. Overall the antigen-specific T cells 
mainly produce IFN-γ and TNF-α and little IL-2 as has been previously described for 
CMV-specific CD8+ T cells. 
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Figure 3 – Cytokine production of CD8+ T cells in response to CMV-epitopes in young donors. A) Gating 
strategy. Single viable lymphocytes were gated on. CD3+ cells were identified and for these CD8+ T cells against 
cytokine production were plotted (B). The percentage of the total CD8+ T cell population producing IFN-γ, IL-2 
and TNF-α are indicated. In all subsequent ICS, CD8+ T cells were gated for in this manner. B) Examples of T cell 
responses of varying magnitude to selected peptide-epitopes studied. The top row shows unstimulated cells served 
as a control. Each row represents staining from an individual donor. 
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Figure 4 – Summary of screening results for all young donors tested A) IFN-γ production. B) IL-2 production. 
C) TNF-α production. The left hand column represents T cell responses to HLA-A restricted epitopes, the middle 
column HLA-B restricted epitopes and the right hand column HLA-C restricted epitopes. The means are indicated 
by horizontal bars. Note the different scales between cytokines and HLA types. Each symbol indicates the 
response from an individual donor.  
 
 
Figure 4 summarises the screening results from all 15 young donors.  CD8+ T cell 
responses were detected against all 14 of the epitopes tested however with varying 
magnitudes. The size of the CD8+ T cell responses ranged from 0.02 to 2.25%. A 
general trend was observed where the CD8+ T cell responses to the HLA-C restricted 
epitopes are larger than both the HLA-A and HLA-B. The HLA-Cw7-restricted FRC 
epitope exhibited a larger TNF-α response than the other two cytokines and elicited 
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the largest overall cytokine responses. The HLA-B responses (in particular the HLA-
B7 restricted RPR epitope) were almost all negative, except for the NEG epitope who 
elicited comparable IFN-γ and TNF-α production (2.31% and 3.98% respectively) to 
the FRC epitope and the HLA-B51 restricted WPK epitope (tested once). The TNF-α 
responses ranged from 0.02% to 2.25%, the IFN-γ from 0.02-2.09% and the IL-2 
production was very small across all HLA-A, HLA-B and HLA-C restricted epitopes 
tested, ranging from 0.04-0.69%. 
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3.3 – Detection of CD8+ T cell specific for CMV-derived epitopes in elderly donors 
 
Previous studies have shown increasing magnitudes of CMV-specific T cell responses 
in elderly donors. However, these were mainly against pp65 or IE-1 derived epitopes. 
Next it was therefore investigated whether a similar increase could be observed for 
these newly identified peptide-epitopes. PBMCs from 15 elderly donors (aged 68– 86 
years) were screened in the same fashion as the young donors.  
 
Example dot plots of four epitope-specific T cell responses in elderly donors are 
shown in Figure 5, demonstrating that a range of response magnitudes against these 
CMV epitopes can be detected. In one donor the CD8+ T cell response to FRC takes 
up 32% and 31% of the CD8+ T cell pool producing IFN-γ and TNF-α respectively, 
whereas  the response to the RTD epitope is much smaller with only about 0.15% and 
0.17% of cells producing IFN-γ and TNF-α respectively (Figure 5). As seen with the 
young donors, the T cells are largely producing IFN-γ and TNF-α  in response to 
antigen stimulation with very little or no IL-2 production. 
37 
 
 
Figure 5 – Frequency of CD8+ T cells responding to CMV epitopes in elderly donors. Shown are example dot 
plots of four selected epitopes. PBMCs were stimulated with peptide and stained to identify IFN-γ, IL-2 and TNF-
α producing CD8+ T cells. Each row represents a CD8+ T cell response detected in an individual donor. 
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Figure 6 - % CD8+ T cells producing cytokines after stimulation with 14 CMV peptide epitopes within 15 
elderly donors A) IFN-γ production. B) IL-2 production. C) TNF-α production. This is figure is as described for 
the summary of young responses in Figure 3.  
 
CD8+ T cell responses against all 12 epitopes tested were detected in the elderly 
donors varying in magnitude (Figure 6). Similar to what was observed within the 
young donors (Figure 4), responses within the elderly to the HLA-B restricted 
epitopes elicited no IL-2 (except the NEG epitope at 0.04-0.07%) production and very 
little IFN-γ. However, the HLA-B7 SPS, YPR and HLA-B35 HPF epitopes elicited 
good TNF-α production in one donor tested with those epitopes (0.85%, 0.65% and 
0.66% respectively). Also similar to observed with the young donors the responses to 
the HLA-A epitopes were a good size ranging from 0.05 to 1.24%. The FRC epitope, 
as in the young donors, elicited the strongest response for all three cytokines at 
32.25%, 31.07% and 4.23% for IFN-γ, TNF-α and IL-2 production respectively.  
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3.4 – Comparison of detected CD8+ T cell responses between young and elderly 
donors 
Although only a small number of donors were screened for T cell responses against 
these new epitopes, frequencies of TNF-α, IFN-γ and IL-2 producing CD8+ T cells 
were compared between young and elderly donors. 
 
 
Figure 7 - Comparison of the CMV-specific CD8+ T cell responses between young and elderly donors A) TNF-
α+ CMV-specific CD8+ T cell response to the epitopes listed. B) IFN-γ+ CMV-specific CD8+ T cell responses to 
the epitopes listed. C) IL-2+ CD8+ T cell responses to the epitopes listed. Represented are mean response sizes 
with SEM. Responses significantly different between the young and elderly donors are indicated by an asterisk and 
have a p value < 0.05. Note the difference in scale between the IFN-γ, TNF-α and IL-2 graphs. 
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The comparison of the average response to each epitope tested in the young vs. 
elderly is shown in Figure 7. The overall results indicate that within the elderly 
donors, there is a trend towards higher frequencies of cells producing IFN-γ and TNF-
α for the majority of epitopes. However, for IL-2 responses the reverse seems to be 
true with the exception of the HLA-C restricted epitopes. The IL-2 responses within 
the elderly are still very small as within the young and do not represent a significant 
% of the total CD8+ T cell pool.  
 
The HLA-C restricted epitopes induced some very large CD8+ T cell responses in 
both young and elderly donors in particular the HLA-Cw0702 restricted epitope FRC.  
It elicits a significantly larger IFN-γ and TNF-α response in the elderly at a ~9 fold 
increase (Figure 7A and B right hand column).  
 
The YLC epitope also elicits CMV-specific CD8+ T cell responses larger than the 
responses seen within the young donors (2-4 fold) but to a lesser extent (Figure 3B 
and 5). The RTD response appeared to have a larger magnitude (0.28 vs. 1% IFN-γ 
and 0.42% vs. 1.24% TNF-γ within the young and elderly respectively) and a more 
defined positive population (Figure 3B and Figure 5). 
 
The raw data can be found within the appendix Tables A3-A8 
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3.5 – Phenotypic analysis of the CMV-specific CD8 T cells towards the newly 
identified antigens 
 
The majority of CMV-specific T cell responses analysed to date display a very 
characteristic phenotype marked by the loss of CCR7 and co-stimulatory molecules 
like CD28 and gain of CD57 expression. In addition they re-express CD45RA even 
though they are antigen experienced.  
 
To assess the phenotype of CD8+ T cells specific for these newly identified epitopes, 
intracellular staining for TNF-α production (to identify the CMV-specific CD8+ T 
cells) was combined with staining for phenotypic surface markers. The co-expression 
of CCR7 and CD45RA was used initially to distinguish cells of distinct memory cell 
compartments (Figure 8A and B).  
 
In general, T cells are separated into four subsets as follows: naïve (CD45RA+, 
CCR7+), central memory (CD45RA-, CCR7+), effector memory (CD45RA-, CCR7-) 
and effector memory RA revertant (EMRA) cells (CD45RA+CD27-) (See schematic 
diagram in Figure 8A).    
 
Here four different epitopes were chosen and analysed in two young and one elderly 
donor. In addition to CCR7 and CD45RA, PBMCs were surface stained for CD57, 
and CD28 to further discriminate their differentiation status (Figure 8C).  
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Figure 8 – Identification of T cell memory subsets: A) Schematic diagram showing the co-expression of CCR7 
and CD45RA used to identify T cell memory subsets. B) FACS plots showing expression of CCR7 and CD45RA 
on epitope-specific T cells. PBMCs were stimulated with the peptide indicated, followed by ICS. CD8+ T cells 
producing TNF-α in response are gated on and displayed here. 
 
 
As shown in Figure 8B, for all epitopes tested the vast majority of the virus-specific 
CD8+ T cells displayed an effector memory phenotype, in particular that of EMRA 
cells (on average 83% of responding CD8+ T cells). The two responses detected in 
young donors contained a slightly lower proportion of EMRA cells, with 70.4% and 
75.4% respectively. This is line with previous findings for pp65 and IE-1 derived 
epitopes. 
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Figure 9 - Phenotype of the CD8+ T cells responding to the new CMV epitopes.  Example FACS plots 
demonstrating the surface levels of CCR7, CD57, CD45RA and CD28 on antigen-specific T cells. CMV-specific 
CD8+ T cells are discriminated by TNF-α production. (left hand column). The subsequent columns show the 
percentage of CMV-specific CD8+ T cells expressing the particular surface molecule. Each row represents data for 
one specific T cell epitope as indicated. 
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In addition to CCR7 and CD45RA, expression of CCR7 and CD28 was analysed on 
TNF-α producing CD8+ T cells. Results are presented in Figure 9. The CMV-specific 
CD8+ T cells from both the two young and single elderly donor largely lacked 
expression of CD28 and had gained expression of CD57. An exception is the FRC 
CD8+ T cell response within one younger donor. Here a larger proportion of 
responding cells still had CD28 on their surface (34%) and the frequency of CD57 
expressing cells was very low with 19.6%. This was in contrast to CD8+ T cells 
responding to the same epitope within the elderly donor (2.6% and 64.0% 
respectively). 
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3.6– Cloning of CD8+ T cells specific for CMV-epitopes 
 
In order to analyse whether ‘protected epitopes’ are recognised within the context of 
virus-infection, two of the detected epitope-specific CD8+ T cell responses were 
cloned. This was done utilising an IFN-γ capture cytokine assay followed by limiting 
dilution cloning (see materials and methods). By IFN-γ ELISA peptide-specific 
clones were detected following overnight co-culture of T cells with autologous 
peptide-pulsed or DMSO-pulsed LCL. DMSO serves as a solvent for the peptides and 
therefore as a control. Figure 10 shows an example result for one such screening 
experiment. 
 
For donor YD4, twenty clones specific for the RTD epitope were identified (clones 
c10, c14, c15, c20, c23, c37, c39, c40, c45, c47, c48, c51, c58, c63, c66, c67, c68, 
c73, c74, c75, c79, c81, c86, c90, c103, c104, c117 and c118) and for donor YD5, 
four specific clones for the YAD epitope were identified (clones c2, c13, c23 and 
c32). RTD specific clones c63, c90 and c104 as well as YAD specific clones c23 and 
c32 were grown up in culture and used for further experiments.  
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Figure 10 – Representative results of an IFN-γ ELISA to identify peptide-specific T cell clones. IFN-γ was 
measured in the supernatant of co-cultures of potential T cell clones with peptide-pulsed or DMSO-pulsed 
autologous LCLs. 
 
 
 
 
 
 
 
 
B) 
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3.7 – Determination of peptide avidity of CD8+ T cell clones 
 
To determine the avidity of the CD8+ T cell clones, peptide titrations were performed. 
For this, autologous LCLs were pulsed with a dilution series of the appropriate 
peptide, co-cultured with the T cell clones and IFN-γ detected within the supernatant 
by ELISA.  
 
As shown in Figure 11, all clones tested had a very high avidity for their respective 
peptides. Peptide dilutions as low as 10
-8
 were able to induce a cytokine response by 
the clones tested. Findings were very similar for all clones, even though the 
magnitude of the response differed considerably between them. This was comparable 
to previous findings in our lab. This was comparable to previous findings for CMV-
specific CD8+ T cell responses. 
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Figure 11  -  Measurement of peptide avidity of RTD and YAD-specific CD8+ T cell clones. A) Peptide avidity 
of clones c63, c90 and c104 specific for the RTD epitope. B) Peptide avidity of  clones  c23 and c32 specific for 
the YAD epitope was determined. The peptide concentration is given along the X-axis. The amount of IFN-γ 
produced is given along the Y-axis in pg/ml. 
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3.8 – CD8+ T cell recognition of CMV-infected fibroblasts 
 
In the final experiment of this study, it was analysed whether the epitope-specific 
CD8+ T cells were able to recognise naturally processed and presented antigen. It was 
also investigated whether these two epitopes are presented by cells infected with WT-
CMV strain (AD169) in comparison to the deletion mutant RV798. 
 
Fibroblasts were infected for 48hours with either AD169 or RV798 virus strains at an 
M.O.I. of 0.5 and 0.05. This time was chosen as it allows the US gene products to 
exert their MHC I down regulatory effects. After 48 hours, CD8+ T cells specific for 
the relevant epitope were added overnight and IFN-γ production measured in an 
ELISA (Figure 12).  
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Figure 12 – T cell recognition of virus-infected fibroblasts. Clones c90, c104 (RTD-specific) and c23 and c32 
(YAD-specific) were stimulated with uninfected fibroblasts, AD169 at M.O.I. 0.5, AD1659 at M.O.I. 0.05, RV798 
at M.O.I 0.5 and RV798 at M.O.I. 0.05. IFN-γ in the supernatant was detected by ELISA. Supernatants were used 
neat or 1/10 diluted to ensure accurate measurements of the cytokine. The amount of IFN-γ produced is given 
along the Y-axis in pg/ml.  
 
 
For both specificities the results indicate that the epitopes are only sufficiently 
presented by fibroblasts during infection with deletion virus RV798 (Figure 12). No 
CD8+ T cell recognition was observed when the cells were infected with the WT 
strain AD169 which expressed the immune evasion proteins. Recognition of RV798 
infection was only seen with an M.O.I. of 0.5.  
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CHAPTER 4 - DISCUSSION 
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CMV-driven proliferation and accumulation of CD8+ T cells within the elderly 
(termed memory inflation) can take up substantial fractions of the host total CD8+ T 
cell pool. This has been hypothesised to impact upon the health of elderly donors. 
CMV encodes for several immumomodulatory genes that protect CMV-derived 
antigens from CD8+ T cell recognition. However CMV-specific responses to such 
antigens can be detected within the peripheral blood of young and elderly individuals 
when PBMCs are co-cultured in vitro with fibroblasts infected with a CMV-strain 
deleted for immunoevasins. Further understanding the characteristics, functionally 
and phenotypically of the CD8+ T cell responses to these ‘protected’ CMV-antigens 
and how they change over time may allow us to address whether these cells behave 
differently in vivo in comparison to ‘non-protected’ responses and also indicate, 
whether in humans, stable or inflationary epitopes can be discriminated as they have 
been within the murine model. The results from this investigation support the 
previous findings of memory inflation of CMV-specific CD8+ T cells, the same 
characteristic phenotype and identified epitopes that may dominate the immune 
response as seen for some pp65 and IE-1-derived epitopes. 
 
4.1 – Detection and magnitude of CD8+ T cell responses in young vs. elderly donors 
 
In an attempt to characterise the CMV-specific CD8+ T cell response to newly 
identified CMV-derived peptide-epitopes (Stan Riddell, unpublished), PBMCs of 15 
young and 15 elderly individuals were screened. Peptide stimulation was combined 
with intracellular cytokine staining for IFN-γ, IL-2 and TNF-α production to identify 
activated T cells. Immune  responses were detected to all epitopes tested within this 
study (Table 3) derived from the UL16, UL17, UL23, UL24, UL28, UL33, UL36, 
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UL52, UL56,UL84, UL105, UL122 proteins encoded by the CMV genome. The 15 
young donors responded to all 14 epitopes tested and the elderly to all 12 however at 
varying magnitudes (raw frequencies of cytokine responses and the mean values are 
provided in the appendix). This investigation presents evidence for CD8+ T cell 
responses specific for antigens derived from across the CMV genome. Furthermore, it 
supports the memory inflation hypothesis of CMV-driven accumulation of virus-
specific CD8+ T cells. 
 
The largest T cell responses detected within this study were against the epitope FRC 
(4.23 to 32% of CD8+ T cells) from elderly donors (Figure 5 and 6).  Even within the 
young, the responses to this epitope were also the largest (0.69 to 2.09% of CD8+ T 
cells). The FRC epitope is HLA-Cw0702 restricted and derived from the UL28 protein 
whose function is currently unknown. It is therefore difficult to extrapolate why this 
protein was so immunogenic within these donors. 
 
Large responses were also detected against another HLA-C restricted epitope, YLC, 
derived from the UL24 protein which forms part of the tegument (Table 1) and as seen 
for the FRC epitope, seem to accumulate with age (Figure 7).  Cytokine response 
frequencies within the young donors ranged from 0.04-0.15% (IFN-γ), 0.13% (IL-2) and 
0.28-0.33% (TNF-α). In the elderly these responses ranged from 0.09-12.14% (IFN-γ), 
0.04-1.16% (IL-2) and 0.44-14.22% (TNF-α). The HLA-A1 restricted epitope RTD 
presented with an age-related accumulation with an average IFN-γ and TNF-α response 
within the young and elderly – 0.06%/0.11% and 0.17%/0.30% respectively. The IL-2 
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production remained similar (0.08 and 0.06% respectively). The RTD epitope is derived 
UL69 protein forming part of the tegument. The responses to YLC and RTD epitopes 
could be generated when the virus enters the body, before the US2-11 proteins prevent 
their presentation to the CD8+ T cell response. The primed CD8+ T cells may then be 
driven to proliferate when the virus reactivates during the host’s lifetime. 
 
The CD8+ T cell responses detected against the HLA-B restricted epitopes were rare 
within the donors here investigated and it is therefore difficult to draw any conclusions 
from the data obtained. For example, the WPK and IPH epitopes were tested once within 
young donors but could not be tested within the elderly as none were HLA-B51 positive. 
The HLA-B restricted epitopes (in particular HLA-B7) in the majority induced very little 
or no cytokine producing CD8+ T cell responses in both age groups analysed here 
(Figure 4, 6 and 7) with very minimal IFN-γ (0.05-0.14% young and 0.06-0.19% 
elderly), IL-2 (0.04-0.19% young and 0.04-0.07% elderly) and TNF-α (0.04-0.19% 
young and 0.04-0.56% elderly).  This could be as a result of their negative CD28 surface 
expression (Figure 8C) which will be further discussed in 4.2. It is surprising that the 
immune responses to the YPR and SPS epitopes were low as they are derived from a 
glycoprotein and the tegument respectively (Table 1) and should theoretically elicit 
larger response’s than was observed as these antigens are brought in as part of the virus 
particle. However, these antigens may be presence in a small abundance of the virion and 
therefore not be particularly immunogenic. These low CD8+ T cell responses may also 
be down to the way these antigens are processed for antigen-presentation in vivo. Studies 
by Wolkers et al. demonstrate clear differences in the priming efficiency depending upon 
the epitopes position within the protein
29
. 
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Most virus-specific CD8+ T cells responses to date are restricted through the HLA-A 
and HLA-B molecules. These alleles are known for their presentation of viral peptides to 
the CD8+ T cell population to elicit a CTL response
30
. The HLA-C alleles are also able 
to present peptide
31
, however, HLA-C alleles have been attributed a lesser role in the 
generation of virus-specific CTL responses due to their much lower surface expression 
level (~10% of HLA-A/B)
32
  and in addition they are less stable. It is now generally 
accepted that their main role is as an inhibitory ligand for killer-cell immunoglobulin-
like (KIRs) present on NK cells
33
. This poses a question to why the CMV-specific CD8+ 
T cell responses to the HLA-C restricted epitopes in this study, in particular the FRC 
epitope, are so large. 
 
The down-regulation of HLA-A and HLA-B but not HLA-C has been described for the 
HIV virus by the virus-encoded protein nef
34
. This is in an attempt to evade CTL 
recognition but still remain resistant to NK cell recognition. It is plausible that CMV also 
may down-regulate HLA-C alleles to a lesser extent from the surface of infected cells to 
achieve the same evasion. Studies indicate that this indeed may be the case
35
. This may 
contribute to the particular immunodominance of the HLA-C restricted CD8+ T cells 
responses seen in previous literature and within this investigation. It may also provide a 
mechanism explaining the smaller CMV-specific CTL responses towards the HLA- and 
HLA-B restricted epitopes as these HLA genes have reduced surface expression on 
CMV-infected cells caused by the US gene products.  
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Within the elderly, a general trend towards increased CMV-specific CD8+ T cell 
responses was seen (Figure 4 and 7) which provides early evidence for age-dependent 
accumulation of CD8+ T cell responses to these newly characterised epitopes. This 
correlates with the previous published data on CMV memory inflation
2; 14; 17; 19
. This 
might be slightly surprising as one could think these epitopes would be presented at 
lower levels in vivo by WT-infected cells and therefore represent ‘stable’ epitopes. 
It would be extremely interesting to develop HLA-C tetramers containing CMV-
derived epitopes, especially the FRC epitope. This would allow studying them 
directly ex vivo and further characterising these T cell responses.   
 
4.2 – Phenotype of CD8+ T cells to the newly characterised epitopes 
 
The surface phenotype of the epitope-specific CD8+ T cells analysed within the scope of 
this study correlates with the phenotype that has previously been published for CMV-
specific CD8+ T cell responses (Figure 8C)
2; 14; 15; 16
. The results did suggest that the 
CD8+ T cell responses to the FRC epitope acquire CD57 over time which fits in with the 
previous data (19.6% and 64.0% from a young and a separate elderly donor respectively, 
Figure 8C). However, this was investigated in only one donor. Furthermore, using CCR7 
vs. CD45RA to distinguish memory compartments, the majority of virus-specific CD8+ 
T cells in young and elderly donors display an EMRA phenotype (Figure 8A/B).  Studies 
by Carrasco et al. have shown that antigen-experienced T cells can revert to the 
CD45RA isoform, normally associated with naive T cells, when they have not 
encountered antigen for an extended period of time
36
. This might be an explanation for 
the re-expression of CD45RA on CMV-specific CD8+ T cell expansions. The fact that 
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these CMV-specific CD8+ T cells lack CD28 expression could provide an explanation 
for little IL-2 production seen in response to all the epitopes tested (Figure 8C). The loss 
of CD28 on murine CD8+ T cells has previously been correlated with a reduction in IL-2 
production showing that co-stimulation is essential for induction of this cytokine
37
. There 
appeared to be no major difference in the surface phenotype of the CD8+ T cells 
responding to the four epitopes tested, between the young and elderly donors. The next 
step in the investigation would first of all be to extend the phenotype study to more 
young and elderly donors to allow more definite comparisons to be made. The second 
would be to perform cytotoxicity assays to further assess the functionality of these 
CMV-specific CD8+ T cells. 
 
4.3– Recognition of processed and presented CMV peptide epitopes during WT 
infection 
 
The results from the fibroblast recognition assay show that in vitro the WT virus is 
masking the T cells from recognising HLA-A1 restricted epitopes RTD and YAD. 
However, as this investigation has demonstrated CMV-specific CD8+ T cell 
responses against these two epitopes can be found in vivo, which opens the question 
to how these CD8+ T cell responses are being generated. The first explanation could 
be that these CD8+ T cell responses recognise these epitopes before the US gene 
products impair MHC I presentation. To investigate this possibility fibroblast 
recognition assays should be repeated with shorter infection times. This will shed 
light on whether the CD8+ T cell clones can recognise epitopes during WT infection 
before the MHC I evasion gene products have exerted their effects.  
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A second explanation could be cross-priming of the CD8+ T cells by DCs. Exogenous 
antigens can be taken up by professional APCs, enter the MHC I pathway and be 
presented to CD8+ cells
38
. This has been hypothesised to contribute to the CMV-
specific CTL priming in vitro. CTL responses to pp65 have been observed in the 
context of non-permissive DCs that have ingested CMV-infected fibroblasts
39
. In vivo 
studies with MCMV by Busche et al. confirm that cross-presentation plays an 
important role in the priming of virus-specific CD8+ T cell responses
40
. 
 
 
4.4 - Future research and final Conclusion 
 
Altogether, the evidence indicates that CMV infection drives the adaptive immune 
response towards oligoclonality responsible in part for immune senescence and is, to 
date, the largest documented response against a viral agent. Understanding the 
magnitude and kinetics of both the CD4+ and CD8+ responses within young vs. elderly 
donors will help to identify CMV-derived epitopes that elicit stable vs. inflationary 
CD8+ T cell responses as has been characterised within the murine model. To date it still 
remains to be investigated whether the accumulation of CMV-specific CD8+ T cells 
occurs with other antigens from the CMV genome and this investigation made a first 
attempt. Preliminary experiments within this study indicate that the CD8+ T cell 
responses to the newly identified CMV peptide epitopes display the same characteristic 
phenotype being CCR7
-
/CD28
-
/CD45RA
+
/CD57
+ 
and responses to some epitopes 
accumulate with age. However, it is not known which role they play in vivo in 
controlling the virus. It might therefore be interesting to study T cell responses to these 
‘protected’ epitopes in an immune suppressed setting.  
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CHAPTER 5 - APPENDIX 
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HLA Type 
Donor Age HLA-A HLA-B HLA-C 
YD1 48 
A2  
A11 B50 B35 Cw0401, Cw0602 
YD2 48 A1 A29 B44 B57 Cw0602, Cw1601 
YD3 59 A1 B8 Cw7 
YD4 27 A1 A32 B8 B14 Cw701, Cw0802 
YD5 53 A1 A3 B8 B18 Cw0501, CW0701 
YD6 49 
A29, 
A30 B7 B45 Cw06, Cw07 
YD7 30 A3 A24 B58 B35 Cw0302 Cw 0401 
YD8 52 A1 A2  B8 B27 Cw0101, Cw0701 
YD9 47 A2 A3  B15 B60 Cw9, Cw3 
YD10 49 A1 A2 
B12(44) 
B17 Cw0401 
YD11 45 A1 A11  B51 B37 Cw0401, Cw0602 
YD12 44 A2 A24 B27 B35 Cw0202, Cw04 
YD13 52 A3 A29 B7 Cw0702  
YD14 29 A3 A31 B7 B44 Cw0702 Cw1601 
YD15 30 A1 A2 B8 B15 Cw0701 Cw0704 
 
Average 44 
    
Table A1 – HLA types and age of the 15 young donors 
 
 
  
HLA Type 
Donor Age HLA-A HLA-B HLA-C 
OD33 68 A1 B8 B57 Cw6 
OD04 78 A1 A2 B8 B44 Cw0701 Cw1601 
ODO7 86 A1 A11 B7 B8 Cw0701 Cw0702 
OD01 80 A3 A29 B8 B44 Cw7 Cw1601 
OD08 83 A1 A2 B8 - 
OD12 86 A24 A68 B7 B44 Cw0702 Cw1601 
0D21 77 A1 A2 
B38 
B60 - 
OD26 
(CMV 
neg) - - - - 
OD28 81 A1 A2 B8 B62 Cw0701 
OD10 not known A11/CW   - 
OD11 79 A1 A2 B7, B35 Cw0702 
OD27 81 A2 A11 B7 B44 Cw0702 
OD14 80 A2 A33 
B39 
B65 - 
OD25 79 A1 A11 B8 B35 Cw0701 
OD24 74 A2 B7 - 
OD30 71 A2 A11 B7 B27 Cw0702 
 
 Average 74 
 
 
 
  
 
Table A2 – HLA types and age of the 16 elderly donors 
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Table A3 - Frequencies of IFN-γ producing CD8+ T cell responses in young healthy donors 
 
 
 
IL-2 
              
Donor: 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
B51-
IPH 
B51-
WPK 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
YD1 - - - 0.10 - - - 0.15 - - - - - - 
YD2 0.04 0.04 - - - - - - 0.13 - - - - 0.13 
YD3 0.00 0.05 - - - - - - - - - - - - 
YD4 0.04 0.00 - - - - - - - - - - - - 
YD5 0.19 0.22 0.13 - - - - - - - - 0.10 0.00 - 
YD6 - - - - 0.07 0.12 0.04 - - - - 0.29 0.10 - 
YD7 - - 0.09 - - - - 0.19 - - - - - - 
YD8 0.00 0.17 - - - - - - - - - - - - 
YD9 - - 0.00 - - - - - - - - - - - 
YD10 0.00 0.00 - - - - - - 0.07 - - - - - 
YD11 0.27 0.13 - 0.14 - - - - - 0.09 0.32 - - - 
YD12  -  - -   - -   - -  0.00  -  - -   - -   - 
YD13  -  - 0.00  - 0.00 0.00 0.00  - -   -  - 0.69 0.00  - 
YD14  - -   -  - 0.00 0.00 0.00  - 0.08  -  - 0.10 0.00 0.00 
YD15 0.07 0.10  - -   - -   - -   - -   - -   - -  
Average 0.08 0.09 0.05 0.07 0.02 0.04 0.01 0.10 0.14 0.09 0.32 0.30 0.03 0.06 
 
 
Table A4 – Frequencies of IL-2 producing CD8+ T cell responses in young healthy donors. 
 
 
 
IFN 
              
Donor: 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
B51-
IPH 
B51-
WPK 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
YD1  - - - 0.05 - - - 0.05 - - - - - - 
YD2 0.00 0.04 - - - - - - 2.31 - - - - 0.04 
YD3 0.28 0.05 - - - - - - - - - - - - 
YD4 0.03 0.00 - - - - - - - - - - - - 
YD5 0.00 0.16 0.00 - - - - - - - - 0.00 0.00 - 
YD6  - - - - 0.00 0.08 0.00 - - - - 1.28 0.04 - 
YD7  - - 0.00 - - - - 0.14 - - - - - - 
YD8 0.00 0.16 - - - - - - - - - - - - 
YD9 - - 0.00 - - - - - - - - - - - 
YD10 0.00 0.00 - - - - - - 0.07 - - - - - 
YD11 0.17 0.13 - 0.27 - - - - - 0.07 0.09 - - - 
YD12 - - - - - - - 0.00   - - - - - 
YD13 - - 0.00 - 0.00 0.00 - - - - - 2.09 0.00 - 
YD14 - - - - 0.00 0.00 0.00 - 0.00 - - 0.39 0.00 0.14 
YD15 0.02 0.00 -  - - - - - - - - - - - 
Average 0.06 0.07 0.00 0.16 0.00 0.00 0.00 0.06 0.79 0.07 0.09 0.94 0.01 0.09 
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Table A5 – Frequencies of TNF-α producing CD8+ T cell responses in young healthy donors 
 
 
 
Table A6 - Frequencies of IFN-γ producing CD8+ T cell responses in elderly donors. 
TNF 
              
Donors 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
B51-
IPH 
B51-
WPK 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
YD1 - - - 0.05 - - - 0.10 - - - - - - 
YD2 0.16 0.28 - - - - - - 3.98 - - - - 0.33 
YD3 0.05 0.00 - - - - - - - - - - - - 
YD4 0.04 0.00 - - - - - - - - - - - - 
YD5 0.16 0.27 0.12 - - - - - - - - 0.15 0.00 - 
YD6 - - - - 0.00 0.04 0.04 - - - - 1.25 0.07 - 
YD7 - - 0.92 - - - - 0.56 - - - - - - 
YD8 0.00 0.64 - - - - - - - - - - - - 
YD9 - - 0.00 - - - - - - - - - - - 
YD10 0.00 0.00 - - - - - - 0.18 - - - - - 
YD11 0.42 0.16 - 0.36 - - - - - 0.05 0.16 - - - 
YD12  -  - -   - -  -  -  0.00  -  - -   -  -  - 
YD13  -  - 0.00  - 0.00 0.00 0.00  - -   -  - 2.25 0.00  - 
YD14  - -   -  - 0.00 0.00 0.00  - 0.00  -  - 0.47 0.00 0.28 
YD15 0.02 0.02  - -   -  -  - -   - -   - - - -  
Average 0.11 0.17 0.26 0.18 0.00 0.01 0.01 0.28 2.08 0.05 0.16 1.03 0.02 0.31 
IFN 
            
Donor 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
OD33 1.00 0.16 -   - -   - -   - -   - -   - 
ODO4 0.00 0.00  -  -  -  -  -  - 0.00  -  - 0.00 
OD07 0.00 0.00  -  - 0.00 0.00 0.00  -  - 32.25 0.00 12.19 
OD01  -  - 0.00  -  -  -  -  - 0.00 0.00 0.05 0.09 
OD08 0.58 0.00  -  - 0.00 0.00 0.00  -  - 0.00 0.34 0.00 
OD12  -  -  -  - 0.00 0.00 0.00  - 0.06 1.68 0.00 0.00 
OD21 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD26 
(CMV 
neg) 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD28 0.15 0.05  -  -  -  -  -  -  -  -  -  - 
OD10 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD11 0.00 0.28  -  -  - 0.10 0.19 0.19  - 4.88 0.08 0.40 
OD27  -  -  - 0.06 0.06 0.00 0.00  - 0.00 6.91 0.00 0.24 
OD14  -  -  -  -  -  -  -  -  -  -  -  - 
OD25 0.00 0.05  - 0.03 - -   - 0.00  -  -  -  - 
OD24  -  -  - -  0.00 0.00 0.00  -  - -   - -  
OD30  - -   - 0.64 0.00 0.00 0.00 -   - 4.81 0.00 0.56 
Average 0.17 0.05 0.00 0.24 0.01 0.01 0.03 0.10 0.01 3.61 0.03 0.96 
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Table A7 - Raw % frequencies of IL-2 producing CD8+ T cell responses in elderly donors. 
 
 
TNF 
            
Donor: 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
OD33 1.24 0.37 -   - -   - -   - -   - -   - 
ODO4 0.00 0.00  -  -  -  -  -  - 0.00  -  - 0.00 
OD07 0.00 0.00  -  - 0.00 0.00 0.00  -  - 31.07 0.00 14.22 
OD01  -  - 0.00  -  -  -  -  - 0.00 0.00 0.12 0.00 
OD08 0.53  -  -  - 0.00 0.00 0.00  -  - 0.00 0.29 0.00 
OD12  -  -  -  - 0.00 0.00 0.00  - 0.13 2.71 0.00 0.00 
OD21 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD26 
(CMV 
neg) 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD28 0.17 0.05  -  -  -  -  -  -  -  -  -  - 
OD10 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD11 1.04 0.91  -  -  - 0.85 0.65 0.66  - 6.03 0.41 1.16 
OD27  -  -  - 0.03 0.06 0.03 0.03  - 0.00 7.34 0.03 0.44 
OD14  -  -  -  -  -  -  -  -  -  -  -  - 
OD25 0.00 0.05  -  -  - -   - 0.00  -  -  -  - 
OD24  -  -  - -  0.00 0.00 0.00  -  - -   - -  
OD30  - -   - 0.67 0.00 0.00 0.00 -   - 6.15 0.00 1.67 
Average 0.30 0.14 0.00 0.35 0.01 0.13 0.10 0.33 0.03 3.81 0.06 1.25 
 
 
Table A8 - Frequencies of TNF-α producing CD8+ T cell responses in elderly donors 
IL-2 
            
Donor: 
A1-
RTD 
A1-
YAD 
A3-
RVD 
A11-
RSA 
B7-
RPR 
B7-
SPS 
B7-
YPR 
B35-
HPF 
B44-
NEG 
Cw7-
FRC 
Cw7-
SYR 
Cw16-
YLC 
OD33 0.29 0.09 -   - -   - -   - -   - -   - 
ODO4 0.00 0.07  -  -  -  -  -  - 0.00  -  - 0.00 
OD07 0.00 0.00  -  - 0.00 0.00 0.00  -  - 4.23 0.00 1.16 
OD01 -   - 0.00  -  -  -  -  - 0.04 0.07 0.05 0.04 
OD08 0.21 0.00  -  - 0.00 0.00 0.00  -  - 0.00 0.19 0.00 
OD12  -  -  -  - 0.00 0.00 0.00  - 0.06 0.12 0.00 0.00 
OD21 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD26 
(CMV 
neg) 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD28 0.10 0.05  -  -  -  -  -  -  -  -  -  - 
OD10 0.00 0.00  -  -  -  -  -  -  -  -  -  - 
OD11 0.00 0.00  -  -  -  - 0.00 0.00  - 0.29 0.00 0.00 
OD27  -  -  - 0.00 0.00 0.00 0.00  - 0.07 0.86 0.00 0.00 
OD14  -  -  -  -  -  -  -  -  -  -  -  - 
OD25 0.00 0.08  - 0.00  - -   - 0.00  -  -  -  - 
OD24  -  -  - -  0.00 0.00 0.00  -  - -   - -  
OD30  - -   - 0.22 0.00 0.00 0.00 -   - 0.58 0.00 0.09 
Average 0.06 0.03 0.00 0.07 0.00 0.00 0.00 0.00 0.04 0.44 0.02 0.09 
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